|
Gregg J. Stark
Stark Law Offices, P.C.
Call us. Anytime. Anyplace.
|
|
In need of a Top Indiana Drug Defense
Lawyer?
When the time has come
for the services of an Indiana Drug Crime Attorney
you've come to the right place.
The successful results
we have obtained for our clients in every
county in Indiana have not happened by
accident, but by
hard work and valuable experience. We
are drug defense attorneys in Indiana committed
to
justice. When in need of a top quality
drug defense lawyer in Indiana, we know how to help
you! |
|
INDIANA
DRUG CRIME DEFENSE IS WHAT WE DO |
|
|
At Stark Law Offices,
P.C. we know the hardships imposed on those who may have made a
mistake through the use or sale of drugs. Whether it be from
prescription fraud offenses to marijuana or cocaine usage, we
are here to ensure that you are not taken advantage of. When it
comes to the specifics of working through a drug related
prosecution, call us. We've been there. For many
clients, distance or time constraints often make it difficult to
visit with us. Please know that although Stark Law Office, P.C.
has convenient Indiana office locations, it is not always necessary to
visit our offices to fully consult with us or retain us to
represent you. Whether you choose to visit with us or simply
consult by phone, one call puts us in your court anywhere in
Indiana! |
|
Convenient
Indiana Locations |
Within Central
Indiana: (317) 273-8888
Outside
Central Indiana:
888-44-44-LAW (529)
|
IC 35-48
ARTICLE 48. CONTROLLED SUBSTANCES
IC 35-48-1
Chapter 1. Definitions
IC 35-48-1-1
Repealed
(Repealed by P.L.5-1988, SEC.208.)
IC 35-48-1-2
Definitions; application
Sec. 2. The definitions in this chapter apply throughout this
article.
As added by P.L.5-1988, SEC.182.
IC 35-48-1-3
"Administer" defined
Sec. 3. "Administer" means the direct application of a
controlled substance, whether by injection, inhalation,
ingestion, or any other means, to the body of a patient or
research subject by:
(1) a practitioner or by his authorized agent; or
(2) the patient or research subject at the direction and in the
presence of the practitioner.
As added by P.L.5-1988, SEC.183.
IC 35-48-1-4
"Advisory committee" defined
Sec. 4. "Advisory committee" refers to the controlled substances
advisory committee established under IC 35-48-2-1.
As added by P.L.5-1988, SEC.184.
IC 35-48-1-5
"Agent" defined
Sec. 5. "Agent" means an authorized person who acts on behalf
of, or at the direction of, a manufacturer, distributor, or
dispenser, but it does not include a common or contract carrier,
public warehouseman, or employee of the carrier or warehouseman.
As added by P.L.5-1988, SEC.185.
IC 35-48-1-6
"Board" defined
Sec. 6. "Board" refers to the Indiana state board of pharmacy.
As added by P.L.5-1988, SEC.186.
IC 35-48-1-7
"Cocaine" defined
Sec. 7. "Cocaine" includes coca leaves and any salt, compound,
or derivative of coca leaves, and any salt, compound, isomer,
derivative, or preparation which is chemically equivalent or
identical to any of these substances. However, decocainized coca
leaves or extraction of coca leaves that do not contain cocaine
or ecgonine are not included.
As added by P.L.5-1988, SEC.187.
IC 35-48-1-8
Repealed
(Repealed by P.L.3-1989, SEC.224.)
IC 35-48-1-9
"Controlled substance" defined
Sec. 9. "Controlled substance" means a drug, substance, or
immediate precursor in schedule I, II, III, IV, or V under:
(1) IC 35-48-2-4, IC 35-48-2-6, IC 35-48-2-8, IC 35-48-2-10, or
IC 35-48-2-12, if IC 35-48-2-14 does not apply; or
(2) a rule adopted by the board, if IC 35-48-2-14 applies.
As added by P.L.5-1988, SEC.189.
IC 35-48-1-9.3
"Controlled substance analog" defined
Sec. 9.3. (a) "Controlled substance analog" means a substance:
(1) the chemical structure of which is substantially similar to
that of a controlled substance included in chedule I or II and
that has; or
(2) that a person represents or intends to have; a narcotic,
stimulant, depressant, or hallucinogenic effect on the central
nervous system substantially similar to or greater than the
narcotic, stimulant, depressant, or hallucinogenic effect on the
central nervous system of a controlled substance included in
schedule I or II.
(b) The definition set forth in subsection (a) does not include:
(1) a controlled substance;
(2) a substance for which there is an approved new drug
application;
(3) a substance for which an exemption is in effect for
investigational use by a person under Section 505 of the federal
Food, Drug and Cosmetic Act (chapter 675, 52 Stat. 1052 (21
U.S.C. 355)), to the extent that conduct with respect to the
substance is permitted under the exemption; or
(4) a substance to the extent not intended for human consumption
before an exemption takes effect regarding the substance.
As added by P.L.225-2003, SEC.1.
IC 35-48-1-10
"Counterfeit substance" defined
Sec. 10. "Counterfeit substance" means a controlled substance
which, or the container or labeling of which, without
authorization, bears the trademark, trade name, or other
identifying mark, imprint, number, or device, or any likeness
thereof, of a manufacturer, distributor, or dispenser other than
the person who in fact
manufactured, distributed, or dispensed the substance.
As added by P.L.5-1988, SEC.190.
IC 35-48-1-11
"Delivery" defined
Sec. 11. "Delivery" means:
(1) an actual or constructive transfer from one (1) person to
another of a controlled substance, whether or not there is an
agency relationship; or
(2) the organizing or supervising of an activity described in
subdivision (1).
As added by P.L.5-1988, SEC.191. Amended by P.L.165-1990, SEC.1.
IC 35-48-1-12
"Dispense" defined
Sec. 12. "Dispense" means to deliver a controlled substance to
an ultimate user or research subject by or pursuant to the
lawful order of a practitioner and includes the prescribing,
administering, packaging, labeling, or compounding necessary to
prepare the substance for that delivery.
As added by P.L.5-1988, SEC.192.
IC 35-48-1-13
"Dispenser" defined
Sec. 13. "Dispenser" means a practitioner who dispenses.
As added by P.L.5-1988, SEC.193.
IC 35-48-1-14
"Distribute" defined
Sec. 14. "Distribute" means to deliver other than by
administering or dispensing a controlled substance.
As added by P.L.5-1988, SEC.194.
IC 35-48-1-15
"Distributor" defined
Sec. 15. "Distributor" means a person who distributes.
As added by P.L.5-1988, SEC.195.
IC 35-48-1-16
"Drug" defined
Sec. 16. "Drug" has the meaning set forth in IC 16-42-19-2. It
does not include devices or their components, parts, or
accessories, nor does it include food.
As added by P.L.5-1988, SEC.196. Amended by P.L.2-1993,
SEC.190.
IC 35-48-1-17
"Immediate precursor" defined
Sec. 17. "Immediate precursor" means a substance which the board
has found to be and by rule designates as being the principal
compound commonly used or produced primarily for use, and which
is an immediate chemical intermediate used or likely to be used
in the manufacture of a controlled substance, the control of
which is necessary to prevent, curtail, or limit manufacture.
As added by P.L.5-1988, SEC.197.
IC 35-48-1-18
"Manufacture" defined
Sec. 18. "Manufacture" means:
(1) the production, preparation, propagation, compounding,
conversion, or processing of a controlled substance, either
directly or indirectly by extraction from substances of natural
origin, independently by means of chemical synthesis, or by a
combination of extraction and chemical synthesis, and includes
any packaging or repackaging of the substance or labeling or
relabeling of its container. It does not include the
preparation, compounding, packaging, or labeling of a controlled
substance:
(A) by a practitioner as an incident to his administering or
dispensing of a controlled substance in the course of his
professional practice; or
(B) by a practitioner, or by his authorized agent under his
supervision, for the purpose of, or as an incident to, research,
teaching, or chemical analysis and not for sale; or
(2) the organizing or supervising of an activity described in
subdivision (1).
As added by P.L.5-1988, SEC.198. Amended by P.L.165-1990,
SEC.2; P.L.17-2001, SEC.18.
IC 35-48-1-19
"Marijuana" defined
Sec. 19. "Marijuana" means any part of the plant genus Cannabis
whether growing or not; the seeds thereof; the resin extracted
from any part of the plant, including hashish and hash oil; any
compound, manufacture, salt, derivative, mixture, or preparation
of the plant, its seeds or resin. It does not include the mature
stalks of the plant; fiber produced from the stalks; oil or cake
made from the seeds of the plant; any other compound,
manufacture, salt, derivative, mixture, or preparation of the
mature stalks (except the resin extracted therefrom); or the
sterilized seed of the plant which is incapable of germination.
As added by P.L.5-1988, SEC.199.
IC 35-48-1-20
"Narcotic drug" defined
Sec. 20. "Narcotic drug" means any of the following, whether
produced directly or indirectly by extraction from substances of
vegetable origin, independently by means of chemical synthesis,
or by a combination of extraction and chemical synthesis:
(1) Opium and opiate, and any salt, compound, derivative, or
preparation of opium or opiate.
(2) Any salt, compound, isomer, derivative, or preparation
thereof which is chemically equivalent or identical to any of
the substances referred to in subdivision (1) of this
definition, but not including the isoquinoline alkaloids of
opium.
(3) Opium poppy and poppy straw.
As added by P.L.5-1988, SEC.200.
IC 35-48-1-21
"Opiate" defined
Sec. 21. "Opiate" means a substance having an addiction-forming
or addiction-sustaining liability similar to morphine or being
capable of conversion into a drug having addiction-forming or
addiction-sustaining liability. It does not include, unless
specifically designated as controlled under IC 35-48-2, the
dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its
salts (dextromethorphan). It does include its racemic and
levorotatory forms.
As added by P.L.5-1988, SEC.201.
IC 35-48-1-22
"Opium poppy" defined
Sec. 22. "Opium poppy" means the plant of the species Papaver
somniferum L., except its seeds.
As added by P.L.5-1988, SEC.202.
IC 35-48-1-23
"Poppy straw" defined
Sec. 23. "Poppy straw" means any part, except the seeds, of the
opium poppy, after mowing.
As added by P.L.5-1988, SEC.203.
IC 35-48-1-24
"Practitioner" defined
Sec. 24. "Practitioner" means a physician, dentist,
veterinarian, scientific investigator, pharmacy, hospital, or
other institution or individual licensed, registered, or
otherwise permitted to distribute, dispense, conduct research
with respect to, or administer a controlled substance in the
course of professional practice or research in Indiana.
As added by P.L.5-1988, SEC.204.
IC 35-48-1-25
"Prescription drug" defined
Sec. 25. "Prescription drug" means a controlled substance or a
legend drug (as defined in IC 16-18-2-199).
As added by P.L.5-1988, SEC.205. Amended by P.L.2-1993,
SEC.191.
IC 35-48-1-26
"Production" defined
Sec. 26. "Production" includes the manufacture, planting,
cultivation, growing, or harvesting of a controlled substance.
As added by P.L.5-1988, SEC.206.
IC 35-48-1-27
"Ultimate user" defined
Sec. 27. "Ultimate user" means a person who lawfully possesses a
controlled substance for the person's own use, for the use of a
member of the person's household, or for administering to an
animal owned by the person or by a member of the person's
household.
As added by P.L.5-1988, SEC.207.
________________________________________
IC 35-48-2
Chapter 2. Classification of Drugs
IC 35-48-2-1
Considerations of board in determinations on substances;
controlled substances advisory committee; exclusion of a
nonnarcotic substance from schedule
Sec. 1. (a) The board shall administer this article and may
recommend to the general assembly the addition, deletion, or
rescheduling of all substances listed in the schedules in
sections 4, 6, 8, 10, and 12 of this chapter by submitting in an
electronic format under IC 5-14-6 a report of such
recommendations to the legislative council. In making a
determination regarding a substance, the board shall consider
the following:
(1) The actual or relative potential for abuse.
(2) The scientific evidence of its pharmacological effect, if
known.
(3) The state of current scientific knowledge regarding the
substance.
(4) The history and current pattern of abuse.
(5) The scope, duration, and significance of abuse.
(6) The risk to public health.
(7) The potential of the substance to produce psychic or
physiological dependence liability.
(8) Whether the substance is an immediate precursor of a
substance already controlled under this article.
(b) After considering the factors enumerated in subsection (a),
the board shall make findings and recommendations concerning the
control of the substance if it finds the substance has a
potential for abuse.
(c) If the board finds that a substance is an immediate
precursor, substances which are precursors of the controlled
precursor shall not be subject to control solely because they
are precursors of the controlled precursor.
(d) If any substance is designated or rescheduled to a more
restrictive schedule as a controlled substance under federal law
and notice is given to the board, the board shall recommend
similar control of the substance under this article in the
board's report to the general assembly, unless the board objects
to inclusion or rescheduling. In that case, the board shall
publish the reasons for objection and afford all interested
parties an opportunity to be heard. At the conclusion of the
hearing, the board shall publish its findings.
(e) If a substance is rescheduled to a less restrictive schedule
or deleted as a controlled substance under federal law, the
substance is rescheduled or deleted under this article. If the
board objects to inclusion, rescheduling, or deletion of the
substance, the board shall
notify the chairman of the legislative council not more than
thirty (30) days after the federal law is changed and the
substance may not be rescheduled or deleted until the conclusion
of the next complete session of the general assembly. The notice
from the board to the chairman of the legislative council must
be published.
(f) There is established a sixteen (16) member controlled
substances advisory committee to serve as a consultative and
advising body to the board in all matters relating to the
classification, reclassification, addition to, or deletion from
of all substances classified as controlled substances in
schedules I to IV or substances not controlled or yet to come
into being. In addition, the advisory committee shall conduct
hearings and make recommendations to the board regarding
revocations, suspensions, and restrictions of
registrations as provided in IC 35-48-3-4. All hearings shall be
conducted in accordance with IC 4-21.5-3. The advisory committee
shall be made up of:
(1) two (2) physicians licensed under IC 25-22.5, one (1) to be
elected by the medical licensing board of Indiana from among its
members and one (1) to be appointed by the governor;
(2) two (2) pharmacists, one (1) to be elected by the state
board of pharmacy from among its members and one (1) to be
appointed by the governor;
(3) two (2) dentists, one (1) to be elected by the state board
of dentistry from among its members and one (1) to be appointed
by the governor;
(4) the state toxicologist or the designee of the state
toxicologist;
(5) two (2) veterinarians, one (1) to be elected by the state
board of veterinary medical examiners from among its members and
one (1) to be appointed by the governor;
(6) one (1) podiatrist to be elected by the board of podiatric
medicine from among its members;
(7) one (1) advanced practice nurse with authority to prescribe
legend drugs as provided by IC 25-23-1-19.5 who is:
(A) elected by the state board of nursing from among the board's
members; or
(B) if a board member does not meet the requirements under IC
25-23-1-19.5 at the time of the vacancy on the advisory
committee, appointed by the governor;
(8) the superintendent of the state police department or the
superintendent's designee;
(9) three (3) members appointed by the governor who have
demonstrated expertise concerning controlled substances; and
(10) one (1) member appointed by the governor who is a
psychiatrist with expertise in child and adolescent psychiatry.
(g) All members of the advisory committee elected by a board
shall serve a term of one (1) year and all members of the
advisory committee appointed by the governor shall serve a term
of four (4) years. Any elected or appointed member of the
advisory committee,
may be removed for cause by the authority electing or appointing
the member. If a vacancy occurs on the advisory committee, the
authority electing or appointing the vacating member shall elect
or appoint a successor to serve the unexpired term of the
vacating member. The board shall acquire the recommendations of
the advisory committee pursuant to administration over the
controlled substances to be or not to be included in schedules I
to V, especially in the implementation of scheduled substances
changes as provided in subsection (d).
(h) Authority to control under this section does not extend to
distilled spirits, wine, or malt beverages, as those terms are
defined or used in IC 7.1, or to tobacco.
(i) The board shall exclude any nonnarcotic substance from a
schedule if that substance may, under the Federal Food, Drug,
and Cosmetic Act or state law, be sold over the counter without
a prescription.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.344, SEC.1; P.L.137-1985, SEC.17; P.L.200-1987, SEC.4;
P.L.188-1989, SEC.4; P.L.33-1993, SEC.73; P.L.163-1994, SEC.2;
P.L.177-1997, SEC.8; P.L.14-2000, SEC.77; P.L.107-2002, SEC.31;
P.L.28-2004, SEC.178.
IC 35-48-2-1.1
Repealed
(Repealed by P.L.2-1995, SEC.140.)
IC 35-48-2-1.5
Advisory committee; officers; meetings; rules; per diem;
expenses Sec. 1.5.
(a) The advisory committee shall annually elect a chairperson
and any other officers that the advisory committee determines
necessary from among its members.
(b) Meetings of the advisory committee may be called by:
(1) the advisory committee chairperson; or
(2) a majority of the members of the advisory committee.
(c) Seven (7) members of the committee constitute a quorum.
(d) Notwithstanding IC 1-1-4-1, if at least a quorum of its
members are present at a meeting, the committee may take an
action by an affirmative vote of at least a majority of the
members present and voting.
(e) The advisory committee shall adopt rules under IC 4-22-2 to:
(1) set standards related to the registration and control of the
manufacture, distribution, and dispensing of controlled
substances, including record keeping requirements;
(2) set fees described in IC 25-1-8; and
(3) carry out its responsibilities under IC 35-48-2 through IC
35-48-3.
(f) The Indiana professional licensing agency shall provide
staff and facilities to the advisory committee under IC 25-1-5.
(g) Each member of the committee who is not a state employee is
entitled to the minimum salary per diem provided by IC
4-10-11-2.1(b). Such a member is also entitled to reimbursement
for traveling expenses and other expenses actually incurred in
connection with the member's duties, as provided in the state
travel policies and procedures established by the department of
administration and approved by the budget agency.
(h) Each member of the committee who is a state employee is
entitled to reimbursement for traveling expenses and other
expenses actually incurred in connection with the member's
duties, as provided in the state travel policies and procedures
established by the
department of administration and approved by the budget agency.
As added by P.L.200-1987, SEC.5. Amended by P.L.1-2006,
SEC.546.
IC 35-48-2-2
Nomenclature
Sec. 2. Nomenclature. The controlled substances listed in the
schedules in sections 4, 6, 8, 10 and 12 of this chapter are
included by whatever official, common, usual, chemical, or trade
name designated. The number placed in brackets after each
substance is its federal Drug Enforcement Administration
Controlled Substances Code Number which is to be used for
identification purposes on certain certificates of registration.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979,
P.L.303, SEC.2.
IC 35-48-2-3
Schedule I tests
Sec. 3. (a) The board shall recommend placement of a substance
in schedule I under this chapter if it finds that the substance:
(1) has high potential for abuse; and
(2) has no accepted medical use in treatment in the United
States or lacks accepted safety for use in treatment under
medical supervision.
(b) The board may recommend placement of a substance in schedule
I under this chapter if it finds that the substance is
classified as a controlled substance in schedule I under federal
law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987,
SEC.6.
IC 35-48-2-4
Schedule I
Sec. 4. (a) The controlled substances listed in this section are
included in schedule I.
(b) Opiates. Any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers, unless specifically excepted by rule of the board or
unless listed in another schedule, whenever the existence of
these isomers, esters, ethers, and salts is possible within the
specific chemical designation:
Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-
piperidinyl]-N-phenylacetamide) (9815)
Acetylmethadol (9601)
Allylprodine (9602)
Alpha -methyl t h i of e n t a nyl (N- [ 1-methyl -2-( 2 -
thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide) (9832)
Alphacetylmethadol (9603)
Alphameprodine (9604)
Alphamethadol (9605)
Alphamethylfentanyl (9814)
Benzethidine (9606)
Beta-hydroxy-3-methylfentanyl (9831). Other name:
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide.
B e t a -h yd r o x yf e n t a n yl (N- [ 1 - ( 2 -h ydroxy- 2 -
phenethyl)-4-piperidinyl]-N-phenylpropanamide) (9830)
Betacetylmethadol (9607)
Betameprodine (9608)
Betamethadol (9609)
Betaprodine (9611)
Clonitazene (9612)
Dextromoramide (9613)
Diampromide (9615)
Diethylthiambutene (9616)
Difenoxin (9168)
Dimenoxadol (9617)
Dimepheptanol (9618)
Dimethylthiambutene (9619)
Dioxaphetyl butyrate (9621)
Dipipanone (9622)
Ethylmethylthiambutene (9623)
Etonitazene (9624)
Etoxeridine (9625)
Furethidine (9626)
Hydroxypethidine (9627)
Ketobemidone (9628)
Levomoramide (9629)
Levophenacylmorphan (9631)
3-Methylfentanyl
[N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenyl-propanimide](9813)
3-Methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
(9833)
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) (9961)
Morpheridine (9632)
N-[ 1 -benzyl -4-piperidyl ] -N-phenylpropanami d e (benzylfentanyl),
including any isomers, salts, or salts of isomers (9818)
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
including any isomers, salts, or salts of isomers (9834)
Noracymethadol (9633)
Norlevorphanol (9634)
Normethadone (9635)
Norpipanone (9636)
P a r a - f l u o r o f e n t anyl (N- ( 4 - f l u o r o p hen y
l ) -N- [1-(2-phenethyl)-4-piperidinyl] propanamide (9812)
Phenadoxone (9637)
Phenampromide (9638)
Phenomorphan (9647)
Phenoperidine (9641)
PEPAP [1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine] (9663)
Piritramide (9642)
Proheptazine (9643)
Properidine (9644)
Propiram (9649)
Racemoramide (9645)
Thiofentanyl (N-phenyl-N-[
1-(2-thienyl)ethyl-4-piperidinyl]-propanamide) (9835)
Tilidine (9750)
Trimeperidine (9646)
(c) Opium derivatives. Any of the following opium derivatives,
their salts, isomers, and salts of isomers, unless specifically
excepted by rule of the board or unless listed in another
schedule, whenever the existence of these salts, isomers, and
salts of isomers is possible within the specific chemical
designation:
Acetorphine (9319)
Acetyldihydrocodeine (9051)
Benzylmorphine (9052)
Codeine methylbromide (9070)
Codeine-N-Oxide (9053)
Cyprenorphine (9054)
Desomorphine (9055)
Dihydromorphine (9145)
Drotebanol (9335)
Etorphine (except hydrochloride salt) (9056)
Heroin (9200)
Hydromorphinol (9301)
Methyldesorphine (9302)
Methyldihydromorphine (9304)
Morphine methylbromide (9305)
Morphine methylsulfonate (9306)
Morphine-N-Oxide (9307)
Myrophine (9308)
Nicocodeine (9309)
Nicomorphine (9312)
Normorphine (9313)
Pholcodine (9314)
Thebacon (9315)
(d) Hallucinogenic substances. Any material, compound, mixture,
or preparation which contains any quantity of the following
hallucinogenic, psychedelic, or psychogenic substances, their
salts, isomers, and salts of isomers, unless specifically
excepted by rule of the board or unless listed in another
schedule, whenever the existence of these salts, isomers, and
salts of isomers is possible within the specific chemical
designation:
(1) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine (7473). Other name:
TCPy.
(2) 4-Bromo-2, 5-Dimethoxyamphetamine (7391). Some trade o r o t
h e r n a m e s : 4 - B r o m o - 2 ,
5-Dimethoxy-a-methylphenethylamine; 4-Bromo-2, 5-DMA.
(3) 4-Bromo-2, 5-dimethoxphenethylamine (7392). Some trade or
other names:
2-[4-bromo-2,5-dimethoxyphenyl]-1-aminoethane; alpha-desmethyl
DOB; 2C-B, Nexus.
(4) 2, 5-Dimethoxy-4-ethylamphet-amine (7399). Other name: DOET.
(5) 2, 5-Dimethoxy-4-(n)-propylthiophenethylamine (7348). Other
name: 2C-T-7.
(6) 2, 5-Dimethoxyamphetamine (7396). Some trade or other names:
2, 5-Dimethoxy-a-methylphenethylamine; 2, 5-DMA.
(7) 4-Methoxyamphetamine (7411). Some trade or other names: 4 -M
e t h o x y - a - m e t h y l p h e n e t h y l a m i n e ;
Paramethoxyamphetamine; PMA.
(8) 5-Methoxy-3, 4-methylenedioxy amphetamine (7401). Other
Name: MMDA.
(9) 5-Methoxy-N, N-diisopropyltryptamine, including any isomers,
salts, or salts of isomers (7439). Other name: 5-MeO-DIPT.
(10) 4-methyl-2, 5-dimethoxyamphetamine (7395). Some trade a n d
o t h e r n a m e s : 4 - m e t h y l - 2 ,
5-dimethoxy-a-methylphenethylamine; DOM; and STP.
(11) 3, 4-methylenedioxy amphetamine (7400). Other name: MDA.
(12) 3,4-methylenedioxy-N-ethylamphetamine (7404). Other names:
N-ethyl-alpha-methyl-3,4(methylenedioxy) phenethylamine; N-ethyl
MDA; MDE; and MDEA.
(13) 3, 4-methylenedioxymethamphetamine (MDMA) (7405).
(14) 3, 4, 5-trimethoxy amphetamine (7390). Other name:TMA.
(15) Alpha-ethyltryptamine (7249). Some trade and other n a m e
s : E t r y p t a m i n e ; M o n a s e ;
[alpha]-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
[alpha]-ET; and AET.
(16) Alpha-methyltryptamine (7432). Other name: AMT.
(17) Bufotenine (7433). Some trade and other names: 3 -( B -Dime
t h yl ami no e t h y l ) - 5 -h yd r o x yi n d o l e ;
3-(2-dimethylaminonethyl)-5-indolol; N, N-dimethylserotonin;
5-hydroxy-N, N-dimethyltryptamine; mappine.
(18) Diethyltryptamine (7434). Some trade or other names: N, N-Diethyltryptamine;
DET.
(19) Dimethyltrytamine (7435). Some trade or other names: DMT.
(20) Ibogaine (7260). Some trade and other names: 7-Ethyl-6, 6b,
7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-pyrido
(1', 2': 1, 2, azepino 4, 5-b) indole;
tabernanthe iboga.
(21) Lysergic acid diethylamide (7315). Other name: LSD.
(22) Marijuana (7360).
(23) Mescaline (7381).
(24) Parahexyl (7374). Some trade or other names:
3-Hexyl-1-hydroxy-7, 8, 9, 10-Tetrahydro-6, 6,
9-trimethyl-6H-dibenzo (b,d) pyran; Snyhexyl.
(25) Peyote (7415), including:
(A) all parts of the plant that are classified botanically as
lophophora williamsii lemaire, whether growing or not;
(B) the seeds thereof;
(C) any extract from any part of the plant; and
(D) every compound, manufacture, salt, derivative, mixture, or
preparation of the plant, its seeds, or extracts.
(26) N-ethyl-3-piperidyl benzilate (7482). Other name: DMZ.
(27) N-hydroxy-3,4-methylenedioxyamphetamine (7402). Other n a m
e s : N - h y d r o x y - a l p h a - m e t h y l - 3 , 4 (methylenedioxy)phenethylamine;
and N-hydroxy MDA.
(28) N-methyl-3-piperidyl benzilate (7484). Other name: LBJ.
(29) Psilocybin (7437).
(30) Psilocyn (7438).
(31) Tetrahydrocannabinols (7370), including synthetic
equivalents of the substances contained in the plant, or in the
resinous extractives of Cannabis, sp. and synthetic substances,
derivatives, and their isomers with similar chemical structure
and pharmacological activity such as:
(A) B1 cis or trans tetrahydrocannabinol, and their optical
isomers;
(B) B6 cis or trans tetrahydrocannabinol, and their optical
isomers; and 4
(C) B3, cis or trans tetrahydrocannabinol, and their optical
isomers.
Since nomenclature of these substances is not internationally
standardized, compounds of these structures, regardless of
numerical designation of atomic positions are covered. Other
name: THC.
(32) Ethylamine analog of phencyclidine (7455). Some trade or
other names: N-Ethyl-1-phenylcyclohexylamine;
(1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl)
ethylamine; cyclohexamine; PCE.
(33) Pyrrolidine analog of phencyclidine (7458). Some trade or y
other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCP ; PHP.
(34) Thiophene analog of phencyclidine (7470). Some trade or
other names: 1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl
Analog of Phencyclidine; TPCP.
(e) Depressants. Unless specifically excepted in a rule adopted
by the board or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of
the following substances having a depressant effect on the
central nervous system, including its salts, isomers, and salts
of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical
designation:
Gamma-hydroxybutyric acid (other names include GHB;
gamma-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate;
sodium oxybutyrate) (2010)
Mecloqualone (2572)
Methaqualone (2565)
(f) Stimulants. Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation that contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts,
isomers, and salts of isomers:
( [ + / -]) cis-4-methylaminorex ( ( [ + / -] ) c i s -4,5-
dihydro-4-methyl-5-phenyl-2-oxazolamine) (1590)
Aminorex (1585). Other names: aminoxaphen; 2 - a m i n o - 5 - p
h e n y l - 2 - o x a z o l i n e ; o r
4,5-dihydro-5-phenyl-2-oxazolamine.
Cathinone (1235). Some trade or other names:
2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone;
2-aminopropiophenone; and norephedrone.
Fenethylline (1503)
N-Benzylpiperazine (7493). Other names: BZP; and
1-benzylpiperazine.
N-ethylamphetamine (1475)
Methcathinone (1237) Some other trade names:
2-Methylamino-1-Phenylpropan-I-one; Ephedrone;
Monomethylpropion; UR 1431.
N, N-dimethylamphetamine (1480). Other names: N,
N-alpha-t r imethyl-benzeneethanamine; and N,
N-alpha-trimethylphenethylamine.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979,
P.L.303, SEC.3; Acts 1981, P.L.170, SEC.2; P.L.333-1983, SEC.1;
P.L.327-1985, SEC.1; P.L.156-1986, SEC.4; P.L.200-1987, SEC.7;
P.L.163-1994, SEC.3; P.L.2-1996, SEC.286; P.L.288-2001, SEC.15;
P.L.22-2008, SEC.1.
IC 35-48-2-5
Schedule II tests
Sec. 5. (a) The board shall recommend placement of a substance
in schedule II under this chapter if it finds that:
(1) the substance has high potential for abuse;
(2) the substance has currently accepted medical use in
treatment in the United States, or currently accepted medical
use with severe restrictions; and
(3) the abuse of the substance may lead to severe psychological
or physical dependence.
(b) The board may recommend placement of a substance in schedule
II under this chapter if it finds that the substance is
classified as a controlled substance in schedule II under
federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987,
SEC.8.
IC 35-48-2-6
Schedule II
Sec. 6. (a) The controlled substances listed in this section are
included in schedule II.
(b) Any of the following substances, except those narcotic drugs
listed in other schedules, whether produced directly or
indirectly by extraction from substances of vegetable origin, or
independently by means of chemical synthesis, or by combination
of extraction and
chemical synthesis:
(1) Opium and opiate, and any salt, compound, derivative, or
preparation of opium or opiate, excluding apomorphine,
dextrorphan, nalbuphine, naloxone, naltrexone, and their
respective salts but including:
(A) raw opium (9600);
(B) opium extracts (9610);
(C) opium fluid extracts (9620);
(D) powdered opium (9639);
(E) granulated opium (9640);
(F) tincture of opium (9630);
(G) codeine (9050);
(H) dihydroetorphine (9334);
(I) ethylmorphine (9190);
(J) etorphine hydrochloride (9059);
(K) hydrocodone (9193);
(L) hydromorphone (9150);
(M) metopon (9260);
(N) morphine (9300);
(O) oxycodone (9143);
(P) oxymorphone (9652); and
(Q) thebaine (9333).
(2) Any salt, compound, isomer, derivative, or preparation
thereof which is chemically equivalent or identical with any of
the substances referred to in subdivision (b)(1) of this
section, but not including the isoquinoline alkaloids of opium.
(3) Opium poppy and poppy straw.
(4) Cocaine (9041).
(5) Concentrate of poppy straw (the crude extract of poppy straw
in either liquid, solid, or powder form which contains the
phenanthrene alkaloids of the opium poppy) (9670).
(c) Opiates. Any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, esters,
and ethers whenever the existence of these isomers, esters,
ethers, and salts is possible within the specific chemical
designation:
Alfentanil (9737)
Alphaprodine (9010)
Anileridine (9020)
Bezitramide (9800)
Bulk dextropropoxyphene (nondosage forms) (9273)
Carfentanil (9743)
Dihydrocodeine (9120)
Diphenoxylate (9170)
Fentanyl (9801)
Isomethadone (9226)
Levo-alphacetylmethadol (9648). Other names:
Levo-alpha-acetylmethadol; levomethadyl acetate; and LAAM.
Levomethorphan (9210)
Levorphanol (9220)
Metazocine (9240)
Methadone (9250)
Methadone-Intermediate, 4-cyano-2-dimethyl-amino-4, 4-diphenyl
butane (9254)
Moramide-Intermediate, 2-methyl-3-morpholino-1,
1-diphenylpropane- carboxylic acid (9802)
Pethidine (Meperidine) (9230)
P e t h i d i n e - I n t e r m e d i a t e - A ,
4-cyano-1-methyl-4-phenylpiperidine (9232)
P e t h i d i n e - I n t e r m e d i a t e - B ,
ethyl-4-phenylpiperidine-4-carboxylate (9233)
Pethidine-Intermediate-C,1-methyl-4-phenylpiperidine-4-carb
oxylic acid (9234)
Phenazodine (9715)
Piminodine (9730)
Racemethorphan (9732)
Racemorphan (9733)
Remifentanil (9739)
Sufentanil (9740)
(d) Stimulants. Any material compound, mixture, or preparation
which contains any quantity of the following substances having a
potential for abuse associated with a stimulant effect on the
central nervous system:
(1) Amphetamine, its salts, optical isomers, and salts of its
optical isomers (1100).
(2) Methamphetamine, including its salts, isomers, and salts of
its isomers (1105).
(3) Phenmetrazine and its salts (1631).
(4) Methylphenidate (1724).
(e) Depressants. Unless specifically excepted by rule of the
board or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of
the following substances having a depressant effect on the
central nervous system, including its salts, isomers, and salts
of isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical
designation:
Amobarbital (2125)
Glutethimide (2550)
Pentobarbital (2270)
Phencyclidine (7471)
Secobarbital (2315)
(f) Immediate precursors. Unless specifically excepted by rule
of the board or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of
the following substances:
(1) Immediate precursor to amphetamine and methamphetamine:
Phenylacetone (8501). Some trade or other names:
phenyl-2-propanone; P2P; benzyl methyl ketone; methyl
benzyl ketone.
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine (7460); or
(B) 1-piperidinocyclohexanecarbonitrile (PCC) (8603).
(g) Hallucinogenic substances:
Nabilone (7379). Other name: (+/-)-trans-3-
(1,1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1-hydroxy-6,
6-dimethyl-9H-dibenzo [b,d] pyran-9-one.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979,
P.L.303, SEC.4; Acts 1981, P.L.170, SEC.3; P.L.333-1983, SEC.2;
P.L.77-1984, SEC.13; P.L.327-1985, SEC.2; P.L.156-1986, SEC.5;
P.L.329-1987, SEC.1; P.L.31-1998, SEC.9; P.L.22-2008, SEC.2.
IC 35-48-2-7
Schedule III tests
Sec. 7. (a) The board shall recommend placement of a substance
in schedule III under this chapter if it finds that:
(1) the substance has a potential for abuse less than the
substances listed in schedule I and II under this chapter;
(2) the substance has currently accepted medical use in
treatment in the United States; and
(3) abuse of the substance may lead to moderate or low physical
dependence or high psychological dependence.
(b) The board may recommend placement of a substance in schedule
III under this chapter if it finds that the substance is
classified as a controlled substance in schedule III under
federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987,
SEC.9.
IC 35-48-2-8
Schedule III
Sec. 8. (a) The controlled substances listed in this section are
included in schedule III.
(b) Stimulants. Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts,
isomers (whether optical, position, or geometric), and salts of
such isomers whenever the existence of such salts, isomers, and
salts of isomers is possible within the specific chemical
designation:
(1) Those compounds, mixtures, or preparations in dosage unit
form containing any stimulant substances listed in schedule II
which compounds, mixtures, or preparations were listed on April
1, 1986, as excepted compounds under 21 CFR 1308.32, and any
other drug of the quantitative composition shown in that list
for those drugs or that is the same except that it contains a
lesser quantity of controlled substances (1405).
(2) Benzphetamine (1228).
(3) Chlorphentermine (1645).
(4) Clortermine (1647).
(5) Phendimetrazine (1615).
(c) Depressants. Unless specifically excepted or unless listed
in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system:
(1) Any compound, mixture, or preparation containing:
(A) amobarbital (2126);
(B) secobarbital (2316);
(C) pentobarbital (2271); or
(D) any of their salts; and one (1) or more other active
medicinal ingredients which are not listed in any schedule.
(2) Any suppository dosage form containing:
(A) amobarbital (2126);
(B) secobarbital (2316);
(C) pentobarbital (2271); or
(D) any of their salts; and approved by the Food and Drug
Administration for marketing only as a suppository.
(3) Any substance which contains any quantity of a derivative of
barbituric acid, or any salt thereof (2100).
(4) Chlorhexadol (2510).
(5) Embutramide (2020).
(6) Lysergic acid (7300).
(7) Lysergic acid amide (7310).
(8) Methyprylon (2575).
(9) Sulfondiethylmethane (2600).
(10) Sulfonethylmethane (2605).
(11) Sulfonmethane (2610).
(12) A combination product containing Tiletamine and Zolazepam
or any salt thereof (Telazol) (7295).
(13) Any drug product containing gamma-hydroxybutyric acid,
including its salts, isomers, and salts of isomers, for which an
application is approved under section 505 of the federal Food,
Drug and Cosmetic Act, 21 U.S.C. 301 et seq. (2012).
(d) Nalorphine (a narcotic drug) (9400).
(e) Narcotic Drugs. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or
preparation containing any of the following narcotic drugs, or
their salts calculated as the free anhydrous base or alkaloid,
in the following
limited quantities:
(1) Not more than 1.8 grams of codeine, per 100 milliliters or
not more than 90 milligrams per dosage unit, with an equal or
greater quantity of an isoquinoline alkaloid of opium (9803).
(2) Not more than 1.8 grams of codeine, per 100 milliliters or
not more than 90 milligrams per dosage unit, with one (1) or
more active, nonnarcotic ingredients in recognized therapeutic
amounts (9804).
(3) Not more than 300 milligrams of dihydrocodeinone, per 100
milliliters or not more than 15 milligrams per dosage unit, with
a fourfold or greater quantity of an isoquinoline alkaloid of
opium (9805).
(4) Not more than 300 milligrams of dihydrocodeinone, per 100
milliliters or not more than 15 milligrams per dosage unit, with
one (1) or more active nonnarcotic ingredients in recognized
therapeutic amounts (9806).
(5) Not more than 1.8 grams of dihydrocodeine, per 100
milliliters or not more than 90 milligrams per dosage unit, with
one (1) or more active, nonnarcotic ingredients in recognized
therapeutic amounts (9807).
(6) Not more than 300 milligrams of ethylmorphine, per 100
milliliters or not more than 15 milligrams per dosage unit, with
one (1) or more active, nonnarcotic ingredients in recognized
therapeutic amounts (9808).
(7) Not more than 500 milligrams of opium per 100 milliliters or
per 100 grams or not more than 25 milligrams per dosage unit,
with one (1) or more active, nonnarcotic ingredients in
recognized therapeutic amounts (9809).
(8) Not more than 50 milligrams of morphine, per 100 milliliters
or per 100 grams with one (1) or more active nonnarcotic
ingredients in recognized therapeutic amounts
(9810).
(9) Buprenorphine (9064).
(f) Anabolic steroid (as defined in 21 U.S.C. 802(41)(A) and 21
U.S.C. 802(41)(B)).
(g) The board shall except by rule any compound, mixture, or
preparation containing any stimulant or depressant substance
listed in subsections (b) through (e) from the application of
any part of this article if the compound, mixture, or
preparation contains one (1) or more active medicinal
ingredients not having a stimulant or depressant effect on the
central nervous system, and if the admixtures are included
therein in combinations, quantity, proportion, or concentration
that vitiate the potential for abuse of the substances
which have a stimulant or depressant effect on the central
nervous system.
(h) Any material, compound, mixture, or preparation which
contains any quantity of Ketamine (7285).
(i) Hallucinogenic substances: Dronabinol (synthetic) in sesame
oil and encapsulated in a soft gelatin capsule in a United
States Food and Drug
Administration approved drug product (7369).
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.2, SEC.86; Acts 1979, P.L.303, SEC.5; Acts 1981, P.L.170,
SEC.4; P.L.333-1983, SEC.3; P.L.200-1987, SEC.10; P.L.48-1991,
SEC.76; P.L.1-1994, SEC.171; P.L.31-1998, SEC.10; P.L.288-2001,
SEC.16; P.L.22-2008, SEC.3.
IC 35-48-2-9
Schedule IV tests
Sec. 9. (a) The board shall recommend placement of a substance
in schedule IV under this chapter if it finds that:
(1) the substance has a low potential for abuse relative to
substances in schedule III under this chapter;
(2) the substance has currently accepted medical use in
treatment in the United States; and
(3) abuse of the substance may lead to limited physical
dependence or psychological dependence relative to the
substances in schedule III under this chapter.
(b) The board may recommend placement of a substance in schedule
IV under this chapter if it finds that the substance is
classified as a controlled substance in schedule IV under
federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987,
SEC.11.
IC 35-48-2-10
Schedule IV
Sec. 10. (a) The controlled substances listed in this section
are included in schedule IV.
(b) Narcotic drugs. Unless specifically excepted in a rule
adopted by the board or unless listed in another schedule, any
material, compound, mixture, or preparation containing any of
the following narcotic drugs, or their salts calculated as the
free anhydrous base or
alkaloid, in the following limited quantities:
(1) Not more than 1 milligram of difenoxin (9618) and not less
than 25 micrograms of atropine sulfate per dosage unit.
(2) Dextropropoxyphene (alpha-
(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane
(9278).
(c) Depressants. Unless specifically excepted in a rule adopted
by the board or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of
the following substances, including its salts, isomers, and
salts of
isomers whenever the existence of such salts, isomers, and salts
of isomers is possible within the specific chemical designation:
Alprazolam (2882).
Barbital (2145).
Bromazepam (2748).
Camazepam (2749).
Carisoprodol.
Chloral betaine (2460).
Chloral hydrate (2465).
Chlordiazepoxide (2744).
Clobazam (2751).
Clonazepam (2737).
Clorazepate (2768).
Clotiazepam (2752).
Cloxazolam (2753).
Delorazepam (2754).
Diazepam (2765).
Dichloralphenazone (2467).
Estazolam (2756).
Ethchlorvynol (2540).
Ethinamate (2545).
Ethyl loflazepate (2758).
Fludiazepam (2759).
Flunitrazepam (2763).
Flurazepam (2767).
Halazepam (2762).
Haloxazolam (2771).
Ketazolam (2772).
Loprazolam (2773).
Lorazepam (2885).
Lormetazepam (2774).
Mebutamate (2800).
Medazepam (2836).
Meprobamate (2820).
Methohexital (2264).
Methylphenobarbital (mephobarbital) (2250).
Midazolam (2884).
Nimetazepam (2837).
Nitrazepam (2834).
Nordiazepam (2838).
Oxazepam (2835).
Oxazolam (2839).
Paraldehyde (2585).
Petrichloral (2591).
Phenobarbital (2285).
Pinazepam (2883).
Prazepam (2764).
Quazepam (2881).
Temazepam (2925).
Tetrazepam (2886).
Triazolam (2887).
Zaleplon (2781).
Zolpidem (Ambien) (2783).
Zopiclone (2784).
(d) Fenfluramine. Any material, compound, mixture, or
preparation which contains any quantity of the following
substances, including its salts, isomers (whether optical,
position, or geometric), and salts of such isomers, whenever the
existence of such salts,
isomers, and salts of isomers is possible.
Fenfluramine (1670).
(e) Stimulants. Unless specifically excepted in a rule adopted
by the board or unless listed in another schedule, any material,
compound, mixture, or preparation which contains any quantity of
the following substances having a stimulant effect on the
central nervous system, including its salts, isomers (whether
optical, position, or geometric), and salts of such isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
Cathine ((+)-norpseudoephedrine) (1230).
Diethylpropion (1610).
Fencamfamin (1760).
Fenproporex (1575).
Mazindol (1605).
Mefenorex (1580).
Modafinil (1680).
Phentermine (1640).
Pemoline (including organometallic complexes and chelates
thereof) (1530).
Pipradrol (1750).
Sibutramine (1675).
SPA ((-)-1-dimethylamino-1,2-diphenylethane (1635).
(f) Other substances. Unless specifically excepted or unless
listed in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances including its salts:
Butorphanol (including its optical isomers) (9720).
Pentazocine (9709).
(g) The board may except by rule any compound, mixture, or
preparation containing any depressant substance listed in
subsection (b), (c), (d), (e), or (f) from the application of
any part of this article if the compound, mixture, or
preparation contains one (1) or more
active medicinal ingredients not having a depressant effect on
the central nervous system, and if the admixtures are included
therein in combinations, quantity, proportion, or concentration
that vitiate the potential for abuse of the substances which
have a depressant effect on the central nervous system.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.344, SEC.2; Acts 1979, P.L.303, SEC.6; Acts 1981, P.L.170,
SEC.5; P.L.333-1983, SEC.4; P.L.77-1984, SEC.14; P.L.200-1987,
SEC.12; P.L.288-2001, SEC.17; P.L.8-2004, SEC.3; P.L.22-2008,
SEC.4.
IC 35-48-2-11
Schedule V tests
Sec. 11. (a) The board shall recommend placement of a substance
in schedule V under this chapter if it finds that:
(1) the substance has low potential for abuse relative to the
controlled substances listed in schedule IV under this chapter;
(2) the substance has currently accepted medical use in
treatment in the United States; and
(3) the substance has limited physical dependence or
psychological dependence liability relative to the controlled
substances listed in schedule IV under this chapter.
(b) The board may recommend placement of a substance in schedule
V under this chapter if it finds that the substance is
classified as a controlled substance in schedule V under federal
law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987,
SEC.13.
IC 35-48-2-12
Schedule V
Sec. 12. (a) The controlled substances listed in this section
are included in schedule V.
(b) Narcotic drugs containing nonnarcotic active medicinal
ingredients. Any compound, mixture, or preparation containing
any of the following narcotic drugs, or their salts calculated
as the free anhydrous base or alkaloid, in the following
quantities, which shall
include one (1) or more nonnarcotic active medicinal ingredients
in sufficient proportion to confer upon the compound, mixture,
or preparation, valuable medicinal qualities other than those
possessed by the narcotic drug alone:
(1) Not more than 200 milligrams of codeine per 100 milliliters
or per 100 grams.
(2) Not more than 100 milligrams of dihydrocodeine per 100
milliliters or per 100 grams.
(3) Not more than 100 milligrams of ethylmorphine per 100
milliliters or per 100 grams.
(4) Not more than 2.5 milligrams of diphenoxylate and not less
than 25 micrograms of atropine sulfate per dosage unit.
(5) Not more than 100 milligrams of opium per 100 milliliters or
per 100 grams.
(6) Not more than 0.5 milligrams of difenoxin (9168), and not
less than 25 micrograms of atropine sulfate per dosage unit.
(c) Pregabalin (2782).
(d) Pyrovalerone (1485).
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979,
P.L.303, SEC.7; Acts 1981, P.L.170, SEC.6; P.L.327-1985, SEC.3;
P.L.22-2008, SEC.5.
IC 35-48-2-13
Repealed
(Repealed by Acts 1979, P.L.303, SEC.13.)
IC 35-48-2-14
Reclassification; rules
Sec. 14. (a) The board may adopt rules under IC 4-22-2 to
reclassify a controlled substance:
(1) from a more restrictive schedule to a less restrictive
schedule; or
(2) as a substance that is not a controlled substance; if the
board finds that the substance qualifies for reclassification
under this chapter and that the same reclassification has been
made in a controlled substance schedule under federal law.
(b) If the board reclassifies a controlled substance under 19
subsection (a), the board shall recommend the same
reclassification to the general assembly under section 1 of this
chapter.
(c) Notwithstanding a provision in this chapter that classifies
a controlled substance in a more restrictive schedule than a
rule adopted under subsection (a), a person who manufactures,
distributes, dispenses, possesses, or uses a controlled
substance in
compliance with the requirements applicable to the less
restrictive schedule to which a controlled substance is
reclassified under subsection (a) does not commit an offense
under this article.
(d) Notwithstanding a provision in this chapter that classifies
a substance as a controlled substance, a person does not commit
an offense under this article if the board has reclassified the
controlled
substance as a substance that is not a controlled substance.
As added by P.L.200-1987, SEC.14.
________________________________________
IC 35-48-3
Chapter 3. Registration and Control
IC 35-48-3-1
Rules
Sec. 1. Rules. The board may promulgate rules and charge
reasonable fees relating to the registration and control of the
manufacture, distribution, and dispensing of controlled
substances within this state.
As added by Acts 1976, P.L.148, SEC.7.
IC 35-48-3-2
Limited permits for entities operating animal shelters Sec. 2.
(a) Any humane society, animal control agency, or governmental
entity operating an animal shelter or other animal
impounding facility is entitled to receive a limited permit only
for the purpose of buying, possessing, and using:
(1) sodium pentobarbital to euthanize injured, sick, homeless,or
unwanted domestic pets and animals;
(2) ketamine and ketamine products to anesthetize or immobilize
fractious domestic pets and animals; and
(3) a combination product containing tiletimine and zolazepam as
an agent for the remote chemical capture of domestic pets or
animals that otherwise cannot be restrained or captured.
(b) A humane society, animal control agency, or governmental
entity entitled to receive a permit under this chapter must: (1)
apply to the board according to the rules established by the
board;
(2) pay annually to the board a fee set by the board for the
limited permit; and (3) submit proof, as determined by the
board, that the employees of an applicant who will handle a
controlled substance are sufficiently trained to use and
administer the controlled substance.
(c) All fees collected by the board under this section shall be
credited to the state board of pharmacy account.
(d) Storage, handling, and use of controlled substances obtained
according to this section are subject to the rules adopted by
the board.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.193-1987,
SEC.16; P.L.136-2001, SEC.1.
IC 35-48-3-3
Registration requirements
Sec. 3. (a) Every person who manufactures or distributes any
controlled substance within this state or who proposes to engage
in the manufacture or distribution of any controlled substance
within this state, must obtain biennially a registration issued
by the board in
accordance with its rules.
(b) Every person who dispenses or proposes to dispense any
controlled substance within Indiana must have a registration
issued by the board in accordance with its rules. A registration
issued to a dispenser under this subsection expires whenever the
dispenser's
license as a practitioner expires. The board shall renew a
dispenser's registration under this subsection concurrently with
any state license authorizing the dispenser to act as a
practitioner.
(c) Persons registered by the board under this article to
manufacture, distribute, dispense, or conduct research with
controlled substances may possess, manufacture, distribute,
dispense, or conduct research with those substances to the
extent authorized by their registration and in conformity with
the other provisions of this chapter.
(d) The following persons need not register and may lawfully
possess controlled substances under this article:
(1) An agent or employee of any registered manufacturer,
distributor, or dispenser of any controlled substance if he is
acting in the usual course of his business or employment.
(2) A common or contract carrier or warehouseman, or an employee
thereof, whose possession of any controlled substance is in the
usual course of business or employment.
(3) An ultimate user or a person in possession of any controlled
substance under a lawful order of a practitioner or in lawful
possession of a schedule V substance.
(e) The board may waive by rule the requirement for registration
of certain manufacturers, distributors, or dispensers if it
finds it consistent with the public health and safety.
(f) A separate registration is required at each principal place
of business or professional practice where the applicant
manufactures, distributes, dispenses, or possesses controlled
substances.
(g) The board may inspect the establishment of a registrant or
applicant for registration in accordance with the board's rules.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.156-1986,
SEC.6.
IC 35-48-3-4
Registration
Sec. 4. Registration. (a) The board shall register an applicant
to manufacture or distribute controlled substances unless it
determines that the issuance of that registration would be
inconsistent with the public interest. In determining the public
interest, the board shall
consider:
(1) maintenance of effective controls against diversion of
controlled substances into other than legitimate medical,
scientific, or industrial channels;
(2) compliance with applicable state and local law;
(3) any convictions of the applicant under any federal and state
laws relating to any controlled substance;
(4) past experience in the manufacture or distribution of
controlled substances, and the existence in the applicant's
establishment of effective controls against diversion;
(5) furnishing by the applicant of false or fraudulent material
in any application filed under this article;
(6) suspension or revocation of the applicant's federal
registration to manufacture, distribute, or dispense controlled
substances as authorized by federal law; and
(7) any other factors relevant to and consistent with the public
health and safety.
(b) Registration under subsection (a) of this section does not
entitle a registrant to manufacture and distribute controlled
substances in schedules I or II other than those specified in
the registration.
(c) Practitioners must be registered to dispense any controlled
substances or to conduct research with controlled substances in
schedules II through V if they are authorized to dispense or
conduct research under the law of this state. The board need not
require
separate registration under this chapter for practitioners
engaging in research with nonnarcotic controlled substances in
schedules II through V where the registrant is already
registered under this chapter in another capacity, to the extent
authorized by his
registration in that other capacity.
(d) Registration to conduct research or instructional activities
with controlled substances in schedules I through V does not
entitle a registrant to conduct research or instructional
activities with controlled substances other than those approved
by the controlled
substances advisory committee in accordance with the
registration. Compliance by manufacturers and distributors with
the provisions of the federal law respecting registration
(excluding fees) entitles them to be registered under this
article.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1981,
P.L.170, SEC.7.
IC 35-48-3-5
Denial, revocation, and suspension of registration;
reinstatement
Sec. 5. (a) An application for registration or re-registration
submitted pursuant to and a registration issued under section 3
of this chapter to manufacture, distribute, or dispense a
controlled substance may be denied, suspended, or revoked by the
board upon a finding by the advisory committee that the
applicant or registrant:
(1) has furnished false or fraudulent material information in
any application filed under this article;
(2) has violated any state or federal law relating to any
controlled substance;
(3) has had his federal registration suspended or revoked to
manufacture, distribute, or dispense controlled substances; or
(4) has failed to maintain reasonable controls against diversion
of controlled substances into other than legitimate medical,
scientific, or industrial channels.
(b) The board may limit revocation or suspension of a
registration or the denial of an application for registration or
re-registration to the particular controlled substance with
respect to which grounds for revocation, suspension, or denial
exist.
(c) If the board suspends or revokes a registration or denies an
application for re-registration, all controlled substances owned
or possessed by the registrant at the time of suspension or the
effective date of the revocation or denial order may be placed
under seal. The board may require the removal of such substances
from the premises. No disposition may be made of substances
under seal until the time for taking an appeal has elapsed or
until all appeals have been concluded unless a court, upon
application therefore, orders the sale of perishable substances
and the deposit of the proceeds of the sale with the court. Upon
a revocation or denial order becoming final, all controlled
substances may be forfeited to the state.
(d) The board shall promptly notify the drug enforcement
administration of all orders suspending or revoking
registration, all orders denying any application for
registration or re-registration, and all forfeitures of
controlled substances.
(e) If the Drug Enforcement Administration terminates, denies,
suspends, or revokes a federal registration for the manufacture,
distribution, or dispensing of controlled substances, a
registration issued by the board under this chapter is
automatically suspended.
(f) The board may reinstate a registration that has been
suspended under subsection (e), after a hearing, if the board is
satisfied that the applicant is able to manufacture, distribute,
or dispense controlled substances with reasonable skill and
safety to the public. As a condition of reinstatement, the board
may impose disciplinary or corrective measures authorized under
IC 25-1-9-9 or this article.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1981,
P.L.170, SEC.8; P.L.197-2007, SEC.93.
IC 35-48-3-6
Order to show cause
Sec. 6. (a) Before recommending a denial, suspension, or
revocation of a registration, or before refusing a renewal of
registration, the advisory committee shall serve upon the
applicant or registrant an order to show cause why registration
should not be
denied, revoked, or suspended, or why the renewal should not be
denied. The order to show cause shall contain a statement of the
basis therefor and shall call upon the applicant or registrant
to appear before the advisory committee at a time and place not
less than thirty (30) days after the date of service of the
order, but in the case of a
denial or renewal of registration the show cause order shall be
served not later than thirty (30) days before the expiration of
the registration. These proceedings shall be conducted in
accordance with IC 4-21.5 without regard to any criminal
prosecution or other proceeding. Proceedings to refuse renewal
of registration shall not abate the existing registration which
shall remain in effect pending the outcome of the administrative
hearing.
(b) The advisory committee may recommend suspension, and the
board may suspend, without an order to show cause, any
registration simultaneously with the institution of proceedings
under section 4 of this chapter, or where renewal of
registration is refused, if it finds that there is an imminent
danger to the public health or safety which warrants this
action. The suspension shall continue in effect until the
conclusion of the proceedings, including judicial review
thereof, unless sooner withdrawn by the board or dissolved by a
court of competent jurisdiction.
(c) If an applicant for re-registration (who is doing business
under a registration previously granted and not revoked nor
suspended) has applied for re-registration at least forty-five
(45) days before the date on which the existing registration is
due to expire, the existing registration of the applicant shall
automatically be extended and continue in effect until the date
on which the board so issues its order. The board may extend any
other existing registration under the circumstances contemplated
in this section even though the registrant failed to apply for
re-registration at least forty-five (45) days before
expiration of the existing registration, with or without request
by the registrant, if the board finds that such extension is not
inconsistent with the public health and safety.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.7-1987,
SEC.166.
IC 35-48-3-7
Records of registrants
Sec. 7. Records of Registrants. Persons registered to
manufacture, distribute, or dispense controlled substances under
this article shall keep records and maintain inventories in
conformance with the record-keeping and inventory requirements
of federal law and with
any additional rules the board issues.
As added by Acts 1976, P.L.148, SEC.7.
IC 35-48-3-8
Order forms
Sec. 8. Order Forms. Controlled substances in schedules I and II
shall be distributed by a registrant to another registrant only
pursuant to an order form. Compliance with the provisions of
federal law respecting order forms is deemed compliance with
this section.
As added by Acts 1976, P.L.148, SEC.7.
IC 35-48-3-9
Prescriptions
Sec. 9. (a) Except for dosages medically required for a period
of not more than forty-eight (48) hours that are dispensed by or
on the direction of a practitioner or medication dispensed
directly by a practitioner, other than a pharmacy, to an
ultimate user, no controlled substance in schedule II may be
dispensed without the written
prescription of a practitioner.
(b) In emergency situations, as defined by rule of the board,
schedule II drugs may be dispensed upon oral prescription of a
practitioner, reduced promptly to writing and filed by the
pharmacy. Prescriptions shall be retained in conformity with the
requirements
of section 7 of this chapter. No prescription for a schedule II
substance may be refilled.
(c) Except for dosages medically required for a period of not
more than forty-eight (48) hours that are dispensed by or on the
direction of a practitioner, or medication dispensed directly by
a practitioner, other than a pharmacy, to an ultimate user, a
controlled substance included in schedule III or IV, which is a
prescription drug as determined under IC 16-42-19, shall not be
dispensed without a written or oral prescription of a
practitioner. The prescription shall not be filled or refilled
more than six (6) months after the date thereof or be refilled
more than five (5) times, unless renewed by the practitioner.
Prescriptions for schedule III, IV, and V controlled substances
may be transmitted by facsimile from the practitioner or the
agent of the practitioner to a pharmacy. The facsimile
prescription is equivalent to an original prescription to the
extent permitted under federal law.
(d) A controlled substance included in schedule V shall not be
distributed or dispensed other than for a medical purpose.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.2-1993,
SEC.192; P.L.163-1994, SEC.4; P.L.204-2005, SEC.21.
IC 35-48-3-10
Repealed
(Repealed by P.L.157-1999, SEC.2.)
IC 35-48-3-11
Treatment for weight reduction or to control obesity
Sec. 11. (a) Only a physician licensed under IC 25-22.5 may
treat a patient with a Schedule III or Schedule IV controlled
substance for the purpose of weight reduction or to control
obesity.
(b) A physician licensed under IC 25-22.5 may not prescribe,
dispense, administer, supply, sell, or give any amphetamine,
sympathomimetic amine drug, or compound designated as a Schedule
III or Schedule IV controlled substance under IC 35-48-2-8
and IC 35-48-2-10 for a patient for purposes of weight reduction
or to control obesity, unless the physician does the following:
(1) Determines:
(A) through review of:
(i) the physician's records of prior treatment of the patient;
or
(ii) the records of prior treatment of the patient provided by a
previous treating physician or weight loss program; that the
physician's patient has made a reasonable effort to
lose weight in a treatment program using a regimen of weight
reduction based on caloric restriction, nutritional counseling,
behavior modification, and exercise without using controlled
substances; and
(B) that the treatment described in clause (A) has been
ineffective for the physician's patient.
(2) Obtains a thorough history and performs a thorough physical
examination of the physician's patient before initiating a
treatment plan using a Schedule III or Schedule IV controlled
substance for purposes of weight reduction or to control
obesity.
(c) A physician licensed under IC 25-22.5 may not begin and
shall discontinue using a Schedule III or Schedule IV controlled
substance for purposes of weight reduction or to control obesity
after the physician determines in the physician's professional
judgment that:
(1) the physician's patient has failed to lose weight using a
treatment plan involving the controlled substance;
(2) the controlled substance has provided a decreasing
contribution toward further weight loss for the patient unless
continuing to take the controlled substance is medically
necessary or appropriate for maintenance therapy;
(3) the physician's patient:
(A) has a history of; or
(B) shows a propensity for; alcohol or drug abuse; or
(4) the physician's patient has consumed or disposed of a
controlled substance in a manner that does not strictly comply
with a treating physician's direction.
As added by P.L.157-1999, SEC.1. Amended by P.L.37-2001, SEC.1.
________________________________________
IC 35-48-4
Chapter 4. Offenses Relating to Controlled Substances
IC 35-48-4-0.5
Controlled substance analog; schedule I controlled substance
Sec. 0.5. For purposes of this chapter, a "controlled substance
analog" is considered to be a controlled substance in schedule I
if the analog is in whole or in part intended for human
consumption.
As added by P.L.225-2003, SEC.2.
IC 35-48-4-1
Dealing in cocaine or narcotic drug
Sec. 1. (a) A person who:
(1) knowingly or intentionally:
(A) manufactures;
(B) finances the manufacture of;
(C) delivers; or
(D) finances the delivery of; cocaine or a narcotic drug, pure
or adulterated, classified in
schedule I or II; or
(2) possesses, with intent to:
(A) manufacture;
(B) finance the manufacture of;
(C) deliver; or
(D) finance the delivery of; cocaine or a narcotic drug, pure or
adulterated, classified in
schedule I or II; commits dealing in cocaine or a narcotic drug,
a Class B felony,
except as provided in subsection (b).
(b) The offense is a Class A felony if:
(1) the amount of the drug involved weighs three (3) grams or
more;
(2) the person:
(A) delivered; or
(B) financed the delivery of; the drug to a person under
eighteen (18) years of age at least
three (3) years junior to the person; or (3) the person
manufactured, delivered, or financed the delivery of the drug:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.96; Acts 1979, P.L.303, SEC.8; P.L.296-1987, SEC.5;
P.L.165-1990, SEC.3; P.L.296-1995, SEC.3; P.L.65-1996, SEC.11;
P.L.17-2001, SEC.19; P.L.151-2006, SEC.22.
IC 35-48-4-1.1
Dealing in methamphetamine
Sec. 1.1. (a) A person who:
(1) knowingly or intentionally:
(A) manufactures;
(B) finances the manufacture of;
(C) delivers; or
(D) finances the delivery of; methamphetamine, pure or
adulterated; or
(2) possesses, with intent to:
(A) manufacture;
(B) finance the manufacture of;
(C) deliver; or
(D) finance the delivery of; methamphetamine, pure or
adulterated; commits dealing in methamphetamine, a Class B
felony, except as provided in subsection (b).
(b) The offense is a Class A felony if:
(1) the amount of the drug involved weighs three (3) grams or
more;
(2) the person:
(A) delivered; or
(B) financed the delivery of; the drug to a person under
eighteen (18) years of age at least
three (3) years junior to the person; or
(3) the person manufactured, delivered, or financed the delivery
of the drug:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by P.L.151-2006, SEC.23.
IC 35-48-4-2
Dealing in a schedule I, II, or III controlled substance
Sec. 2. (a) A person who:
(1) knowingly or intentionally:
(A) manufactures;
(B) finances the manufacture of;
(C) delivers; or
(D) finances the delivery of; a controlled substance, pure or
adulterated, classified in schedule I, II, or III, except
marijuana, hash oil, or hashish; or
(2) possesses, with intent to:
(A) manufacture;
(B) finance the manufacture of;
(C) deliver; or
(D) finance the delivery of; a controlled substance, pure or
adulterated, classified in
schedule I, II, or III, except marijuana, hash oil, or hashish;
commits dealing in a schedule I, II, or III controlled
substance, a Class B felony, except as provided in subsection
(b).
(b) The offense is a Class A felony if:
(1) the person:
(A) delivered; or
(B) financed the delivery of; the substance to a person under
eighteen (18) years of age at
least three (3) years junior to the person; or
(2) the person delivered or financed the delivery of the
substance:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.97; Acts 1979, P.L.303, SEC.9; P.L.296-1987, SEC.6;
P.L.165-1990, SEC.4; P.L.296-1995, SEC.4; P.L.65-1996, SEC.12;
P.L.17-2001, SEC.20.
IC 35-48-4-3
Dealing in a schedule IV controlled substance
Sec. 3. (a) A person who:
(1) knowingly or intentionally:
(A) manufactures;
(B) finances the manufacture of;
(C) delivers; or
(D) finances the delivery of; a controlled substance, pure or
adulterated, classified in
schedule IV; or
(2) possesses, with intent to manufacture or deliver, a
controlled substance, pure or adulterated, classified in
schedule IV; commits dealing in a schedule IV controlled
substance, a Class C felony, except as provided in subsection
(b).
(b) The offense is a Class B felony if:
(1) the person:
(A) delivered; or
(B) financed the delivery of; the substance to a person under
eighteen (18) years of age at
least three (3) years junior to the person; or
(2) the person delivered or financed the delivery of the
substance:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.98; P.L.296-1987, SEC.7; P.L.165-1990, SEC.5;
P.L.296-1995, SEC.5; P.L.65-1996, SEC.13; P.L.17-2001, SEC.21.
IC 35-48-4-4
Dealing in a schedule V controlled substance
Sec. 4. (a) A person who:
(1) knowingly or intentionally:
(A) manufactures;
(B) finances the manufacture of;
(C) delivers; or
(D) finances the delivery of; a controlled substance, pure or
adulterated, classified in
schedule V; or
(2) possesses, with intent to:
(A) manufacture;
(B) finance the manufacture of;
(C) deliver; or
(D) finance the delivery of; a controlled substance, pure or
adulterated, classified in
schedule V; commits dealing in a schedule V controlled
substance, a Class D
felony, except as provided in subsection (b).
(b) The offense is a Class B felony if:
(1) the person:
(A) delivered; or
(B) financed the delivery of; the substance to a person under
eighteen (18) years of age at
least three (3) years junior to the person; or
(2) the person delivered or financed the delivery of the
substance:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.99; P.L.296-1987, SEC.8; P.L.165-1990, SEC.6;
P.L.296-1995, SEC.6; P.L.65-1996, SEC.14; P.L.17-2001, SEC.22.
IC 35-48-4-4.1
Dumping controlled substance waste
Sec. 4.1. (a) A person who dumps, discharges, discards,
transports, or otherwise disposes of:
(1) chemicals, knowing the chemicals were used in the illegal
manufacture of a controlled substance or an immediate precursor;
or
(2) waste, knowing that the waste was produced from the illegal
manufacture of a controlled substance or an immediate precursor;
commits dumping controlled substance waste, a Class D felony.
(b) It is not a defense in a prosecution under subsection (a)
that the person did not manufacture the controlled substance or
immediate precursor.
As added by P.L.17-2001, SEC.23.
IC 35-48-4-4.5
Dealing in a substance represented to be a controlled substance
Sec. 4.5. (a) A person who knowingly or intentionally delivers
or finances the delivery of any substance, other than a
controlled substance or a drug for which a prescription is
required under federal
or state law, that:
(1) is expressly or impliedly represented to be a controlled
substance;
(2) is distributed under circumstances that would lead a
reasonable person to believe that the substance is a controlled
substance; or
(3) by overall dosage unit appearance, including shape, color,
size, markings, or lack of markings, taste, consistency, or any
other identifying physical characteristic of the substance,
would lead a reasonable person to believe the substance is a
controlled
substance; commits dealing in a substance represented to be a
controlled
substance, a Class D felony.
(b) In determining whether representations have been made,
subject to subsection (a)(1), or whether circumstances of
distribution exist, subject to subsection (a)(2), the trier of
fact may consider, in addition to other relevant factors, the
following:
(1) Statements made by the owner or other person in control of
the substance, concerning the substance's nature, use, or
effect.
(2) Statements made by any person, to the buyer or recipient of
the substance, that the substance may be resold for profit.
(3) Whether the substance is packaged in a manner uniquely used
for the illegal distribution of controlled substances.
(4) Whether:
(A) the distribution included an exchange of, or demand for,
money or other property as consideration; and
(B) the amount of the consideration was substantially greater
than the reasonable retail market value of the substance.
As added by Acts 1981, P.L.305, SEC.1. Amended by P.L.210-1986,
SEC.1; P.L.165-1990, SEC.7.
IC 35-48-4-4.6
Unlawful manufacture, distribution, or possession of counterfeit
substance Sec. 4.6. (a) A person who knowingly or intentionally:
(1) manufactures;
(2) finances the manufacture of;
(3) advertises;
(4) distributes; or
(5) possesses with intent to manufacture, finance the
manufacture of, advertise, or distribute; a substance described
in section 4.5 of this chapter commits a Class C felony.
(b) A person who knowingly or intentionally possesses a
substance described in section 4.5 of this chapter commits a
Class C misdemeanor. However, the offense is a Class A
misdemeanor if the person has a previous conviction under this
section.
(c) In any prosecution brought under this section it is not a
defense that the person believed the substance actually was a
controlled substance.
(d) This section does not apply to the following:
(1) The manufacture, financing the manufacture of, processing,
packaging, distribution, or sale of noncontrolled substances to
licensed medical practitioners for use as placebos in
professional practice or research.
(2) Persons acting in the course and legitimate scope of their
employment as law enforcement officers.
(3) The retention of production samples of noncontrolled
substances produced before September 1, 1986, where such samples
are required by federal law.
As added by P.L.210-1986, SEC.2. Amended by P.L.165-1990, SEC.8;
P.L.150-1999, SEC.1; P.L.225-2003, SEC.3.
IC 35-48-4-5
Dealing in a counterfeit substance
Sec. 5. A person who:
(1) knowingly or intentionally:
(A) creates;
(B) delivers; or
(C) finances the delivery of; a counterfeit substance; or
(2) possesses, with intent to:
(A) deliver; or
(B) finance the delivery of; a counterfeit substance; commits
dealing in a counterfeit substance, a Class D felony.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.100; P.L.165-1990, SEC.9.
IC 35-48-4-6
Possession of cocaine or narcotic drug
Sec. 6. (a) A person who, without a valid prescription or order
of a practitioner acting in the course of the practitioner's
professional practice, knowingly or intentionally possesses
cocaine (pure or adulterated) or a narcotic drug (pure or
adulterated) classified in
schedule I or II, commits possession of cocaine or a narcotic
drug, a Class D felony, except as provided in subsection (b).
(b) The offense is:
(1) a Class C felony if:
(A) the amount of the drug involved (pure or adulterated) weighs
three (3) grams or more; or
(B) the person was also in possession of a firearm (as defined
in IC 35-47-1-5);
(2) a Class B felony if the person in possession of the cocaine
or narcotic drug possesses less than three (3) grams of pure or
adulterated cocaine or a narcotic drug:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center; and
(3) a Class A felony if the person possesses the cocaine or
narcotic drug in an amount (pure or adulterated) weighing at
least three (3) grams:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.101; Acts 1979, P.L.303, SEC.10; P.L.138-1983,
SEC.3; P.L.296-1987, SEC.9; P.L.296-1995, SEC.7; P.L.65-1996,
SEC.15; P.L.188-1999, SEC.7; P.L.17-2001, SEC.24; P.L.151-2006,
SEC.24.
IC 35-48-4-6.1
Possession of methamphetamine
Sec. 6.1. (a) A person who, without a valid prescription or
order of a practitioner acting in the course of the
practitioner's professional practice, knowingly or intentionally
possesses methamphetamine (pure or adulterated) commits
possession of methamphetamine, a
Class D felony, except as provided in subsection (b).
(b) The offense is:
(1) a Class C felony if:
(A) the amount of the drug involved (pure or adulterated) weighs
three (3) grams or more; or
(B) the person was also in possession of a firearm (as defined
in IC 35-47-1-5);
(2) a Class B felony if the person in possession of the
methamphetamine possesses less than three (3) grams of pure or
adulterated methamphetamine:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center; and
(3) a Class A felony if the person possesses the methamphetamine
in an amount (pure or adulterated) weighing at least three (3)
grams:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by P.L.151-2006, SEC.25.
IC 35-48-4-7
Possession of a controlled substance; obtaining a schedule V
controlled substance
Sec. 7. (a) A person who, without a valid prescription or order
of a practitioner acting in the course of his professional
practice, knowingly or intentionally possesses a controlled
substance (pure or adulterated) classified in schedule I, II,
III, or IV, except marijuana
or hashish, commi ts possession of a controlled substance, a
Class D felony. However, the offense is a Class C felony if the
person in possession of the controlled substance possesses the
controlled substance:
(1) on a school bus; or
(2) in, on, or within one thousand (1,000) feet of:
(A) school property;
(B) a public park;
(C) a family housing complex; or
(D) a youth program center.
(b) A person who, without a valid prescription or order of a
practitioner acting in the course of his professional practice,
knowingly or intentionally obtains:
(1) more than four (4) ounces of schedule V controlled
substances containing codeine in any given forty-eight (48) hour
period unless pursuant to a prescription;
(2) a schedule V controlled substance pursuant to written or
verbal misrepresentation; or
(3) possession of a schedule V controlled substance other than
by means of a prescription or by means of signing an exempt
narcotic register maintained by a pharmacy licensed by the
Indiana state board of pharmacy; commits a Class D felony.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.102; P.L.138-1983, SEC.4; P.L.327-1985, SEC.4;
P.L.296-1987, SEC.10; P.L.296-1995, SEC.8; P.L.65-1996, SEC.16;
P.L.17-2001, SEC.25.
IC 35-48-4-8
Repealed
(Repealed by Acts 1980, P.L.115, SEC.5.)
IC 35-48-4-8.1
Manufacture of paraphernalia
Sec. 8.1. (a) A person who manufactures, finances the
manufacture of, or designs an instrument, a device, or other
object that is intended to be used primarily for:
(1) introducing into the human body a controlled substance;
(2) testing the strength, effectiveness, or purity of a
controlled substance; or
(3) enhancing the effect of a controlled substance; in violation
of this chapter commits a Class A infraction for manufacturing
paraphernalia.
(b) A person who:
(1) knowingly or intentionally violates this section; and
(2) has a previous judgment for violation of this section;
commits manufacture of paraphernalia, a Class D felony.
As added by Acts 1980, P.L.115, SEC.2. Amended by P.L.202-1989,
SEC.3; P.L.165-1990, SEC.10.
IC 35-48-4-8.2
Repealed
(Repealed by P.L.1-1991, SEC.205.)
IC 35-48-4-8.3
Possession of paraphernalia
Sec. 8.3. (a) A person who possesses a raw material, an
instrument, a device, or other object that the person intends to
use for:
(1) introducing into the person's body a controlled substance;
(2) testing the strength, effectiveness, or purity of a
controlled substance; or
(3) enhancing the effect of a controlled substance; in violation
of this chapter commits a Class A infraction for possessing
paraphernalia.
(b) A person who knowingly or intentionally violates subsection
(a) commits a Class A misdemeanor. However, the offense is a
Class D felony if the person has a prior unrelated judgment or
conviction under this section.
(c) A person who recklessly possesses a raw material, an
instrument, a device, or other object that is to be used
primarily for:
(1) introducing into the person's body a controlled substance;
(2) testing the strength, effectiveness, or purity of a
controlled substance; or
(3) enhancing the effect of a controlled substance; in violation
of this chapter commits reckless possession of paraphernalia, a
Class B misdemeanor. However, the offense is a
Class D felony if the person has a previous judgment or
conviction under this section.
As added by Acts 1980, P.L.115, SEC.4. Amended by P.L.202-1989,
SEC.5; P.L.166-1990, SEC.2; P.L.58-2003, SEC.1.
IC 35-48-4-8.5
Dealing in paraphernalia
Sec. 8.5. (a) A person who keeps for sale, offers for sale,
delivers, or finances the delivery of a raw material, an
instrument, a device, or other object that is intended to be or
that is designed or marketed to be used primarily for:
(1) ingesting, inhaling, or otherwise introducing into the human
body marijuana, hash oil, hashish, or a controlled substance;
(2) testing the strength, effectiveness, or purity of marijuana,
hash oil, hashish, or a controlled substance;
(3) enhancing the effect of a controlled substance;
(4) manufacturing, compounding, converting, producing,
processing, or preparing marijuana, hash oil, hashish, or a
controlled substance;
(5) diluting or adulterating marijuana, hash oil, hashish, or a
controlled substance by individuals; or
(6) any purpose announced or described by the seller that is in
violation of this chapter;
commits a Class A infraction for dealing in paraphernalia.
(b) A person who knowingly or intentionally violates subsection
(a) commits a Class A misdemeanor. However, the offense is a
Class D felony if the person has a prior unrelated judgment or
conviction under this section.
(c) A person who recklessly keeps for sale, offers for sale, or
delivers an instrument, a device, or other object that is to be
used primarily for:
(1) ingesting, inhaling, or otherwise introducing into the human
body marijuana, hash oil, hashish, or a controlled substance;
(2) testing the strength, effectiveness, or purity of marijuana,
hash oil, hashish, or a controlled substance;
(3) enhancing the effect of a controlled substance;
(4) manufacturing, compounding, converting, producing,
processing, or preparing marijuana, hash oil, hashish, or a
controlled substance;
(5) diluting or adulterating marijuana, hash oil, hashish, or a
controlled substance by individuals; or
(6) any purpose announced or described by the seller that is in
violation of this chapter;
commits reckless dealing in paraphernalia, a Class B
misdemeanor. However, the offense is a Class D felony if the
person has a previous judgment or conviction under this section.
(d) This section does not apply to the following:
(1) Items marketed for use in the preparation, compounding,
packaging, labeling, or other use of marijuana, hash oil,
hashish, or a controlled substance as an incident to lawful
research, teaching, or chemical analysis and not for sale.
(2) Items marketed for or historically and customarily used in
connection with the planting, propagating, cultivating, growing,
harvesting, manufacturing, compounding, converting, producing,
processing, preparing, testing, analyzing, packaging,
repackaging, storing, containing, concealing, injecting,
ingesting, or inhaling of tobacco or any other lawful substance.
As added by P.L.1-1991, SEC.206. Amended by P.L.58-2003, SEC.2.
IC 35-48-4-9
Repealed
(Repealed by Acts 1980, P.L.115, SEC.5.)
IC 35-48-4-10
Dealing in marijuana, hash oil, or hashish
Sec. 10. (a) A person who:
(1) knowingly or intentionally:
(A) manufactures;
(B) finances the manufacture of;
(C) delivers; or
(D) finances the delivery of; marijuana, hash oil, or hashish,
pure or adulterated; or
(2) possesses, with intent to:
(A) manufacture;
(B) finance the manufacture of;
(C) deliver; or
(D) finance the delivery of; marijuana, hash oil, or hashish,
pure or adulterated;
commits dealing in marijuana, hash oil, or hashish, a Class A
misdemeanor, except as provided in subsection (b).
(b) The offense is:
(1) a Class D felony if:
(A) the recipient or intended recipient is under eighteen (18)
years of age;
(B) the amount involved is more than thirty (30) grams but less
than ten (10) pounds of marijuana or two (2) grams but less than
three hundred (300) grams of hash oil or hashish;
or
(C) the person has a prior conviction of an offense involving
marijuana, hash oil, or hashish; and
(2) a Class C felony if the amount involved is ten (10) pounds
or more of marijuana or three hundred (300) or more grams of
hash oil or hashish or the person delivered or financed the
delivery of marijuana, hash oil, or hashish:
(A) on a school bus; or
(B) in, on, or within one thousand (1,000) feet of:
(i) school property;
(ii) a public park;
(iii) a family housing complex; or
(iv) a youth program center.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.105; Acts 1979, P.L.303, SEC.11; Acts 1982,
P.L.204, SEC.38; P.L.296-1987, SEC.11; P.L.165-1990, SEC.12;
P.L.296-1995, SEC.9; P.L.65-1996, SEC.17; P.L.17-2001, SEC.26.
IC 35-48-4-11
Possession of marijuana, hash oil, or hashish
Sec. 11. A person who:
(1) knowingly or intentionally possesses (pure or adulterated)
marijuana, hash oil, or hashish;
(2) knowingly or intentionally grows or cultivates marijuana; or
(3) knowing that marijuana is growing on his premises, fails to
destroy the marijuana plants; commits possession of marijuana,
hash oil, or hashish, a Class A
misdemeanor. However, the offense is a Class D felony (i) if the
amount involved is more than thirty (30) grams of marijuana or
two (2) grams of hash oil or hashish, or (ii) if the person has
a prior conviction of an offense involving marijuana, hash oil,
or hashish.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.106; Acts 1979, P.L.303, SEC.12; P.L.138-1983,
SEC.5.
IC 35-48-4-12
Conditional discharge for possession as first offense
Sec. 12. If a person who has no prior conviction of an offense
under this article or under a law of another jurisdiction
relating to controlled substances pleads guilty to possession of
marijuana or hashish as a Class A misdemeanor, the court,
without entering a judgment of conviction and with the consent
of the person, may defer further proceedings and place him in
the custody of the court under such conditions as the court
determines. Upon violation of a condition of the custody, the
court may enter a judgment of conviction. However, if the person
fulfills the conditions of the custody, the court shall dismiss
the charges against him. There may be only one (1) dismissal
under this section with respect to a person.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.107.
IC 35-48-4-13
Visiting or maintaining a common nuisance
Sec. 13. (a) A person who knowingly or intentionally visits a
building, structure, vehicle, or other place that is used by any
person to unlawfully use a controlled substance commits visiting
a common nuisance, a Class B misdemeanor.
(b) A person who knowingly or intentionally maintains a
building, structure, vehicle, or other place that is used one
(1) or more times:
(1) by persons to unlawfully use controlled substances; or
(2) for unlawfully:
(A) manufacturing;
(B) keeping;
(C) offering for sale;
(D) selling;
(E) delivering; or
(F) financing the delivery of; controlled substances, or items
of drug paraphernalia as described in IC 35-48-4-8.5; commits
maintaining a common nuisance, a Class D felony.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.108; P.L.210-1986, SEC.4; P.L.165-1990, SEC.13;
P.L.1-1991, SEC.207; P.L.31-1998, SEC.11; P.L.17-2001, SEC.27.
IC 35-48-4-13.3
Taking juvenile or endangered adult to location used for drug
sale, manufacture, or possession
Sec. 13.3. A person who recklessly, knowingly, or intentionally
takes a person less than eighteen (18) years of age or an
endangered adult (as defined in IC 12-10-3-2) into a building,
structure, vehicle, or other place that is being used by any
person to:
(1) unlawfully possess drugs or controlled substances; or
(2) unlawfully:
(A) manufacture;
(B) keep;
(C) offer for sale;
(D) sell;
(E) deliver; or
(F) finance the delivery of; drugs or controlled substances;
commits a Class A misdemeanor. However, the offense is a Class D
felony if the person has a prior unrelated conviction under this
section.
As added by P.L.225-2003, SEC.4.
IC 35-48-4-14
Offenses relating to registration labeling and prescription
forms
Sec. 14. (a) A person who:
(1) is subject to IC 35-48-3 and who recklessly, knowingly, or
intentionally distributes or dispenses a controlled substance in
violation of IC 35-48-3;
(2) is a registrant and who recklessly, knowingly, or
intentionally:
(A) manufactures; or
(B) finances the manufacture of; a controlled substance not
authorized by his registration or distributes or dispenses a
controlled substance not authorized by his registration to
another registrant or other authorized person;
(3) recklessly, knowingly, or intentionally fails to make, keep,
or furnish a record, a notification, an order form, a statement,
an invoice, or information required under this article; or
(4) recklessly, knowingly, or intentionally refuses entry into
any premises for an inspection authorized by this article;
commits a Class D felony.
(b) A person who knowingly or intentionally:
(1) distributes as a registrant a controlled substance
classified in schedule I or II, except under an order form as
required by
IC 35-48-3;
(2) uses in the course of the:
(A) manufacture of;
(B) the financing of the manufacture of; or
(C) distribution of; a controlled substance a federal or state
registration number that is fictitious, revoked, suspended, or
issued to another person;
(3) furnishes false or fraudulent material information in, or
omits any material information from, an application, report, or
other document required to be kept or filed under this article;
or
(4) makes, distributes, or possesses a punch, die, plate, stone,
or other thing designed to print, imprint, or reproduce the
trademark, trade name, or other identifying mark, imprint, or
device of another or a likeness of any of the foregoing on a
drug or container or labeling thereof so as to render the drug a
counterfeit substance; commits a Class D felony.
(c) A person who knowingly or intentionally acquires possession
of a controlled substance by misrepresentation, fraud, forgery,
deception, subterfuge, alteration of a prescription order,
concealment of a material fact, or use of a false name or false
address commits a Class D felony. However, the offense is a
Class C felony if the person has a prior conviction of an
offense under this subsection.
(d) A person who knowingly or intentionally affixes any false or
forged label to a package or receptacle containing a controlled
substance commits a Class D felony. However, the offense is a
Class C felony if the person has a prior conviction of an
offense under this subsection. This subsection does not apply to
law enforcement agencies or their representatives while engaged
in enforcing IC 16-42-19 or this chapter (or IC 16-6-8 before
its repeal).
(e) A person who duplicates, reproduces, or prints any
prescription pads or forms without the prior written consent of
a practitioner commits a Class D felony. However, the offense is
a Class C felony if the person has a prior conviction of an
offense under this subsection. This subsection does not apply to
the printing of prescription pads or forms upon a written,
signed order placed by a practitioner or pharmacist, by
legitimate printing companies.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977,
P.L.340, SEC.109; P.L.131-1986, SEC.3; P.L.165-1990, SEC.14;
P.L.2-1993, SEC.193.
IC 35-48-4-14.5
Possession or sale of drug precursors
Sec. 14.5. (a) As used in this section, "chemical reagents or
precursors" refers to one (1) or more of the following:
(1) Ephedrine.
(2) Pseudoephedrine.
(3) Phenylpropanolamine.
(4) The salts, isomers, and salts of isomers of a substance
identified in subdivisions (1) through (3).
(5) Anhydrous ammonia or ammonia solution (as defined in IC
22-11-20-1).
(6) Organic solvents.
(7) Hydrochloric acid.
(8) Lithium metal.
(9) Sodium metal.
(10) Ether.
(11) Sulfuric acid.
(12) Red phosphorous.
(13) Iodine.
(14) Sodium hydroxide (lye).
(15) Potassium dichromate.
(16) Sodium dichromate.
(17) Potassium permanganate.
(18) Chromium trioxide.
(19) Benzyl cyanide.
(20) Phenylacetic acid and its esters or salts.
(21) Piperidine and its salts.
(22) Methylamine and its salts.
(23) Isosafrole.
(24) Safrole.
(25) Piperonal.
(26) Hydriodic acid.
(27) Benzaldehyde.
(28) Nitroethane.
(29) Gamma-butyrolactone.
(30) White phosphorus.
(31) Hypophosphorous acid and its salts.
(32) Acetic anhydride.
(33) Benzyl chloride.
(34) Ammonium nitrate.
(35) Ammonium sulfate.
(36) Hydrogen peroxide.
(37) Thionyl chloride.
(38) Ethyl acetate.
(39) Pseudoephedrine hydrochloride.
(b) A person who possesses more than ten (10) grams of
ephedrine, pseudoephedrine, or phenylpropanolamine, pure or
adulterated, commits a Class D felony. However, the offense is a
Class C felony if the person possessed:
(1) a firearm while possessing more than ten (10) grams of
ephedrine, pseudoephedrine, or phenylpropanolamine, pure or
adulterated; or
(2) more than ten (10) grams of ephedrine, pseudoephedrine, or
phenylpropanolamine, pure or adulterated, in, on, or within one
thousand (1,000) feet of:
(A) school property;
(B) a public park;
(C) a family housing complex; or
(D) a youth program center.
(c) A person who possesses anhydrous ammonia or ammonia solution
(as defined in IC 22-11-20-1) with the intent to manufacture
methamphetamine or amphetamine, schedule II controlled
substances under IC 35-48-2-6, commits a Class D felony.
However, the offense is a Class C felony if the person
possessed:
(1) a firearm while possessing anhydrous ammonia or ammonia
solution (as defined in IC 22-11-20-1) with intent to
manufacture methamphetamine or amphetamine, schedule II
controlled substances under IC 35-48-2-6; or
(2) anhydrous ammonia or ammonia solution (as defined in IC
22-11-20-1) with intent to manufacture methamphetamine or
amphetamine, schedule II controlled substances under
IC 35-48-2-6, in, on, or within one thousand (1,000) feet of:
(A) school property;
(B) a public park;
(C) a family housing complex; or
(D) a youth program center.
(d) Subsection (b) does not apply to a:
(1) licensed health care provider, pharmacist, retail
distributor, wholesaler, manufacturer, warehouseman, or common
carrier or an agent of any of these persons if the possession is
in the regular course of lawful business activities; or
(2) person who possesses more than ten (10) grams of a substance
described in subsection (b) if the substance is possessed under
circumstances consistent with typical medicinal or household
use, including:
(A) the location in which the substance is stored;
(B) the possession of the substance in a variety of:
(i) strengths;
(ii) brands; or
(iii) types; or
(C) the possession of the substance:
(i) with different expiration dates; or
(ii) in forms used for different purposes.
(e) A person who possesses two (2) or more chemical reagents or
precursors with the intent to manufacture a controlled substance
commits a Class D felony.
(f) An offense under subsection (e) is a Class C felony if the
person possessed:
(1) a firearm while possessing two (2) or more chemical reagents
or precursors with intent to manufacture a controlled substance;
or
(2) two (2) or more chemical reagents or precursors with intent
to manufacture a controlled substance in, on, or within one
thousand (1,000) feet of:
(A) school property;
(B) a public park;
(C) a family housing complex; or
(D) a youth program center.
(g) A person who sells, transfers, distributes, or furnishes a
chemical reagent or precursor to another person with knowledge
or the intent that the recipient will use the chemical reagent
or precursors to manufacture a controlled substance commits
unlawful sale of a precursor, a Class D felony.
As added by P.L.150-1999, SEC.2. Amended by P.L.17-2001, SEC.28;
P.L.225-2003, SEC.5; P.L.192-2005, SEC.8; P.L.151-2006, SEC.26.
IC 35-48-4-14.7
Sale and storage of drugs containing ephedrine or
pseudoephedrine; application; convenience packages; age
requirements; identification; record keeping; suspicious orders
and unusual thefts
Sec. 14.7. (a) This section does not apply to the following:
(1) Ephedrine or pseudoephedrine dispensed pursuant to a
prescription.
(2) The sale of a drug containing ephedrine or pseudoephedrine
to a licensed health care provider, pharmacist, retail
distributor, wholesaler, manufacturer, or an agent of any of
these persons if the sale occurs in the regular course of lawful
business activities. However, a retail distributor, wholesaler,
or manufacturer is required to report a suspicious order to the
state police department in accordance with subsection (f).
(3) The sale of a drug containing ephedrine or pseudoephedrine
by a person who does not sell exclusively to walk-in customers
for the personal use of the walk-in customers. However, if the
person described in this subdivision is a retail distributor,
wholesaler, or manufacturer, the person is required to report a
suspicious order to the state police department in accordance
with subsection (f).
(b) The following definitions apply throughout this section:
(1) "Constant video monitoring" means the surveillance by an
automated camera that:
(A) records at least one (1) photograph or digital image every
ten (10) seconds;
(B) retains a photograph or digital image for at least
seventy-two (72) hours;
(C) has sufficient resolution and magnification to permit the
identification of a person in the area under surveillance; and
(D) stores a recorded photograph or digital image at a location
that is immediately accessible to a law enforcement officer.
(2) "Convenience package" means a package that contains a drug
having as an active ingredient not more than one hundred twenty
(120) milligrams of ephedrine or pseudoephedrine, or both.
(3) "Ephedrine" means pure or adulterated ephedrine.
(4) "Pseudoephedrine" means pure or adulterated pseudoephedrine.
(5) "Suspicious order" means a sale or transfer of a drug
containing ephedrine or pseudoephedrine if the sale or transfer:
(A) is a sale or transfer that the retail distributor,
wholesaler, or manufacturer is required to report to the United
States Drug Enforcement Administration;
(B) appears suspicious to the retail distributor, wholesaler, or
manufacturer in light of the recommendations contained in
Appendix A of the report to the United States attorney general
by the suspicious orders task force under the federal
Comprehensive Methamphetamine Control Act of 1996; or
(C) is for cash or a money order in a total amount of at least
two hundred dollars ($200).
(6) "Unusual theft" means the theft or unexplained disappearance
from a particular retail store of drugs containing ten (10)
grams or more of ephedrine, pseudoephedrine, or both in a
twenty-four (24) hour period.
(c) This subsection does not apply to a convenience package. A
person may sell a drug that contains the active ingredient of
ephedrine, pseudoephedrine, or both only if the person complies
with the following conditions:
(1) The person does not sell the drug to a person less than
eighteen (18) years of age.
(2) The person does not sell drugs containing more than three
(3) grams of ephedrine or pseudoephedrine, or both in one (1)
transaction.
(3) The person requires:
(A) the purchaser to produce a state or federal identification
card;
(B) the purchaser to complete a paper or an electronic log in a
format approved by the state police department with the
purchaser's name, address, and driver's license or other
identification number; and
(C) the clerk who is conducting the transaction to initial or
electronically record the clerk's identification on the log.
Records from the completion of a log must be retained for at
least two (2) years. A law enforcement officer has the right to
inspect and copy a log or the records from the completion of a
log in accordance with state and federal law. A person may not
sell or release a log or the records from the completion of a
log for a commercial purpose. The Indiana criminal justice
institute may obtain information concerning a log or the records
from the completion of a log from a law enforcement officer if
the information may not be used to identify a specific
individual and is used only for statistical purposes. A retailer
who in good faith releases information maintained under this
subsection is immune from civil liability unless the release
constitutes gross
negligence or intentional, wanton, or willful misconduct. This
subdivision expires June 30, 2012.
(4) The person stores the drug:
(A) behind a counter in an area inaccessible to a customer or in
a locked display case that makes the drug unavailable to a
customer without the assistance of an employee; or
(B) directly in front of the pharmacy counter in the direct line
of sight of an employee at the pharmacy counter, in an area
under constant video monitoring, if the drug is sold in
a retail establishment that:
(i) is a pharmacy; or
(ii) contains a pharmacy that is open for business.
(d) A person may not purchase drugs containing more than three
(3) grams of ephedrine, pseudoephedrine, or both in one (1)
week.
(e) This subsection only applies to convenience packages. A
person may not sell drugs containing more than one hundred
twenty (120) milligrams of ephedrine or pseudoephedrine, or both
in any one (1) transaction if the drugs are sold in convenience
packages. A person who sells convenience packages must secure
the convenience
packages in at least one (1) of the following ways:
(1) The convenience package must be stored not more than thirty
(30) feet away from a checkout station or counter and must be in
the direct line of sight of an employee at the
checkout station or counter.
(2) The convenience package must be protected by a reliable
anti-theft device that uses package tags and detection alarms
designed to prevent theft.
(3) The convenience package must be stored in restricted access
shelving that permits a purchaser to remove not more than one
(1) package every fifteen (15) seconds.
(4) The convenience package must be stored in an area that is
under constant video monitoring, and a sign placed near the
convenience package must warn that the area is under constant
video monitoring.
(f) A retail distributor, wholesaler, or manufacturer shall
report a suspicious order to the state police department in
writing.
(g) Not later than three (3) days after the discovery of an
unusual theft at a particular retail store, the retailer shall
report the unusual theft to the state police department in
writing. If three (3) unusual thefts occur in a thirty (30) day
period at a particular retail store, the retailer shall, for at
least one hundred eighty (180) days after the date of the last
unusual theft, locate all drugs containing ephedrine or
pseudoephedrine at that particular retail store behind a counter
in an area inaccessible to a customer or in a locked display
case that makes the drug unavailable to customers without the
assistance of an employee.
(h) A unit (as defined in IC 36-1-2-23) may not adopt an
ordinance after February 1, 2005, that is more stringent than
this section.
(i) A person who knowingly or intentionally violates this
section commits a Class C misdemeanor. However, the offense is a
Class A misdemeanor if the person has a prior unrelated
conviction under this section.
(j) Before June 30, 2007, the state police department shall
submit a report to the legislative council detailing the
effectiveness of this section in reducing the illicit production
of methamphetamine. The report must describe the number of
arrests or convictions that are attributable to the
identification and logging requirements contained
in this section, and must include recommendations for future
action.
The report must be in an electronic format under IC 5-14-6. As
added by P.L.192-2005, SEC.9. Amended by P.L.151-2006, SEC.27;
P.L.186-2007, SEC.9.
IC 35-48-4-15
Driver's license and motor vehicle registration; suspension
Sec. 15. (a) If a person is convicted of an offense under
section 1, 2, 3, 4, 5, 6, 7, 10, or 11 of this chapter, or
conspiracy to commit an offense under section 1, 2, 3, 4, 5, 6,
7, 10, or 11 of this chapter, and the court finds that a motor
vehicle was used in the commission of the offense, the court
shall, in addition to any other order the court enters, order
that the person's:
(1) operator's license be suspended;
(2) existing motor vehicle registrations be suspended; and
(3) ability to register motor vehicles be suspended; by the
bureau of motor vehicles for a period specified by the court of
at least six (6) months but not more than two (2) years.
(b) If a person is convicted of an offense described in
subsection (a) and the person does not hold an operator's
license or a learner's permit, the court shall order that the
person may not receive an operator's license or a learner's
permit from the bureau of motor vehicles for a period of not
less than six (6) months.
As added by P.L.67-1990, SEC.13. Amended by P.L.107-1991, SEC.3;
P.L.129-1993, SEC.2; P.L.64-1994, SEC.6; P.L.76-2004, SEC.23.
IC 35-48-4-16
Defenses to charge of selling narcotics near school or family
housing
Sec. 16. (a) For an offense under this chapter that requires
proof of:
(1) delivery of cocaine, a narcotic drug, methamphetamine, or a
controlled substance;
(2) financing the delivery of cocaine, a narcotic drug,
methamphetamine, or a controlled substance; or
(3) possession of cocaine, narcotic drug, methamphetamine, or
controlled substance;
within one thousand (1,000) feet of school property, a public
park, a family housing complex, or a youth program center, the
person charged may assert the defense in subsection (b) or (c).
(b) It is a defense for a person charged under this chapter with
an offense that contains an element listed in subsection (a)
that:
(1) a person was briefly in, on, or within one thousand (1,000)
feet of school property, a public park, a family housing
complex, or a youth program center; and
(2) no person under eighteen (18) years of age at least three
(3) years junior to the person was in, on, or within one
thousand (1,000) feet of the school property, public park,
family housing complex, or youth program center at the time of
the offense.
(c) It is a defense for a person charged under this chapter with
an offense that contains an element listed in subsection (a)
that a person was in, on, or within one thousand (1,000) feet of
school property, a public park, a family housing complex, or a
youth program center at the request or suggestion of a law
enforcement officer or an agent of a law enforcement officer.
(d) The defense under this section applies only to the element
of the offense that requires proof that the delivery, financing
of the delivery, or possession of cocaine, a narcotic drug,
methamphetamine, or a controlled substance occurred in, on, or
within one thousand (1,000) feet of school property, a public
park, a family housing complex, or a youth program center.
As added by P.L.17-2001, SEC.29.
IC 35-48-4-17
Restitution for environmental cleanup
Sec. 17. (a) In addition to any other penalty imposed for
conviction of an offense under this chapter involving the
manufacture or intent to manufacture methamphetamine, a court
shall order restitution under IC 35-50-5-3 to cover the costs,
if necessary, of an environmental cleanup incurred by a law
enforcement agency or other person as a result of the offense.
(b) The amount collected under subsection (a) shall be used to
reimburse the law enforcement agency that assumed the costs
associated with the environmental cleanup described in
subsection (a).
As added by P.L.225-2003, SEC.6.
________________________________________
IC 35-48-5
Repealed
(Repealed by P.L.202-1989, SEC.6.)
________________________________________
IC 35-48-6
Repealed
(Repealed by P.L.2-1995, SEC.140.)
________________________________________
IC 35-48-7
Chapter 7. Central Repository for Controlled Substances Data
IC 35-48-7-1
"Advisory committee" defined
Sec. 1. As used in this chapter, "advisory committee" refers to
the controlled substances advisory committee established by
IC 35-48-2-1.
As added by P.L.163-1994, SEC.5 .
IC 35-48-7-2
Repealed
(Repealed by P.L.65-2006, SEC.18.)
IC 35-48-7-2.9
"Dispense" defined
Effective 1-1-2009.
Sec. 2.9. (a) As used in this chapter, "dispense" has the
meaning set forth in IC 35-48-1-12.
(b) The term does not apply to the following:
(1) A drug administered directly to a patient.
(2) A drug dispensed by a practitioner, if the quantity
dispensed is not more than a seventy-two (72) hour supply of a
controlled substance listed in schedule II, III, IV, or V as set
forth in IC 35-48-3-9.
As added by P.L.105-2008, SEC.65.
IC 35-48-7-3 Version a
"Dispenser" defined
Note: This version of section effective until 1-1-2009. See also
following repeal of this section, effective 1-1-2009. Sec. 3. As
used in this chapter, "dispenser" has the meaning set forth in
IC 35-48-1-13. However, the term does not include the following:
(1) A Type II pharmacy (as defined in IC 25-26-13-17) operated
by a hospital licensed under IC 16-21.
(2) A nurse registered or licensed under IC 25-23 or a
medication aide who administers a controlled substance at the
direction of a physician licensed under IC 25-22.5.
(3) A person who administers or dispenses a controlled substance
ordered for a bona fide patient in a facility licensed under IC
16-28.
(4) A pharmacy licensed under IC 25-26-13 when it dispenses
prescriptions ordered for bona fide enrolled patients in
facilities licensed under IC 16-28.
(5) A practitioner who dispenses not more than a forty-eight
(48) hour supply of a controlled substance listed in either
schedule II, III, or IV as set forth in IC 35-48-3-9.
As added by P.L.163-1994, SEC.5.
IC 35-48-7-3 Version b
Repealed
(Repealed by P.L.105-2008, SEC.66.)
Note: This repeal of section effective 1-1-2009. See also
preceding version of this section, effective until 1-1-2009.
IC 35-48-7-4
"Exception report" defined
Sec. 4. As used in this chapter, "exception report" means a
record of data concerning:
(1) a practitioner practicing a particular specialty or field of
health care;
(2) a dispenser doing business in a particular location; or
(3) a recipient; that indicates dispensing or receiving of
controlled substances outside norms for dispensing or receiving
controlled substances established by the advisory committee
under this chapter.
As added by P.L.163-1994, SEC.5.
IC 35-48-7-5
"Identification number" defined
Sec. 5. As used in this chapter, "identification number" refers
to the following:
(1) The unique number contained on any of the following:
(A) A valid driver's license of a recipient or a recipient's
representative issued under Indiana law or the law of any other
state.
(B) A recipient's or a recipient representative's valid military
identification card.
(C) A valid identification card of a recipient or a recipient's
representative issued by:
(i) the bureau of motor vehicles as described in IC 9-24-16-3;
or
(ii) any other state and that is similar to the identification
card issued by the bureau of motor vehicles.
(D) If the recipient is an animal:
(i) the valid driver's license issued under Indiana law or the
law of any other state;
(ii) the valid military identification card; or
(iii) the valid identification card issued by the bureau of
motor vehicles and described in IC 9-24-16-3 or a valid
identification card of similar description that is issued by any
other state; of the animal's owner.
(2) The identification number or phrase designated by the
central repository.
As added by P.L.163-1994, SEC.5. Amended by P.L.204-2005,
SEC.22.
IC 35-48-7-5.2
"INSPECT" defined
Sec. 5.2. As used in this chapter, "INSPECT" means the Indiana
scheduled prescription electronic collection and tracking
program established by IC 25-1-13-4.
As added by P.L.65-2006, SEC.3.
IC 35-48-7-5.4
"Interoperability" defined
Sec. 5.4. As used in this chapter, "interoperability" refers to
the INSPECT program electronically sharing reported information
with another state concerning the dispensing of a controlled
substance:
(1) to a recipient who resides in the other state; or
(2) prescribed by a practitioner whose principal place of
business is located in another state.
As added by P.L.65-2006, SEC.4.
IC 35-48-7-5.6
"Patient" defined
Sec. 5.6. As used in this chapter, "patient" means an individual
who has requested or received health care services from a
provider for the examination, treatment, diagnosis, or
prevention of a physical or mental condition.
As added by P.L.65-2006, SEC.5.
IC 35-48-7-5.8
"Practitioner" defined
Sec. 5.8. As used in this chapter, "practitioner" means a
physician, dentist, veterinarian, podiatrist, nurse
practitioner, scientific investigator, pharmacist, hospital, or
other institution or individual licensed, registered, or
otherwise permitted to distribute, dispense, conduct research
with respect to, or administer a controlled substance in the
course of professional practice or research in the United
States.
As added by P.L.65-2006, SEC.6.
IC 35-48-7-6
"Recipient" defined
Sec. 6. As used in this chapter, "recipient" means an individual
for whom a controlled substance is dispensed.
As added by P.L.163-1994, SEC.5.
IC 35-48-7-7
"Recipient representative" defined
Sec. 7. As used in this chapter, "recipient representative"
means the individual to whom a controlled substance is dispensed
if the recipient is either less than eighteen (18) years of age
or unavailable to receive the controlled substance.
As added by P.L.163-1994, SEC.5.
IC 35-48-7-7.5
"State" defined
Sec. 7.5. As used in this chapter, "state" means any state of
the United States or the District of Columbia.
As added by P.L.65-2006, SEC.7.
IC 35-48-7-8
Repealed
(Repealed by P.L.3-2008, SEC.269.)
IC 35-48-7-8.1
Controlled substance prescription monitoring program;
information; prescription forms
Sec. 8.1. (a) This section applies after June 30, 2007.
(b) The advisory committee shall provide for a controlled
substance prescription monitoring program that includes the
following components:
(1) Each time a controlled substance designated by the advisory
committee under IC 35-48-2-5 through IC 35-48-2-10 is dispensed,
the dispenser shall transmit to the INSPECT
program the following information:
(A) The controlled substance recipient's name.
(B) The controlled substance recipient's or the recipient
representative's identification number or the identification
number or phrase designated by the INSPECT program.
(C) The controlled substance recipient's date of birth.
(D) The national drug code number of the controlled substance
dispensed.
(E) The date the controlled substance is dispensed.
(F) The quantity of the controlled substance dispensed.
(G) The number of days of supply dispensed.
(H) The dispenser's United States Drug Enforcement Agency
registration number.
(I) The prescriber's United States Drug Enforcement Agency
registration number.
(J) An indication as to whether the prescription was transmitted
to the pharmacist orally or in writing.
(K) Other data required by the advisory committee.
(2) The information required to be transmitted under this
section must be transmitted not more than seven (7) days after
the date on which a controlled substance is dispensed.
(3) A dispenser shall transmit the information required under
this section by:
(A) uploading to the INSPECT web site;
(B) a computer diskette; or
(C) a CD-ROM disk; that meets specifications prescribed by the
advisory committee.
(4) The advisory committee may require that prescriptions for
controlled substances be written on a one (1) part form that
cannot be duplicated. However, the advisory committee may not
apply such a requirement to prescriptions filled at a pharmacy
with a Type II permit (as described in IC 25-26-13-17) and
operated by a hospital licensed under IC 16-21, or prescriptions
ordered for and dispensed to bona fide enrolled patients in
facilities licensed under IC 16-28. The committee may not
require multiple copy prescription forms and serially numbered
prescription forms for any prescriptions written. The advisory
committee may not require different prescription forms for any
individual drug or group of drugs. Prescription forms required
under this subdivision must be jointly approved by the committee
and by the Indiana board of pharmacy established by IC
25-26-13-3.
(5) The costs of the program.
As added by P.L.65-2006, SEC.9.
IC 35-48-7-9
Repealed
(Repealed by P.L.65-2006, SEC.18.)
IC 35-48-7-10
Repealed
(Repealed by P.L.3-2008, SEC.269.)
IC 35-48-7-10.1
INSPECT program; designation; powers and duties; funding
Sec. 10.1. (a) This section applies after June 30, 2007.
(b) The INSPECT program must do the following:
(1) Create a data base for information required to be
transmitted under section 8.1 of this chapter in the form
required under rules adopted by the advisory committee,
including search capability for the following:
(A) A controlled substance recipient's name.
(B) A controlled substance recipient's or recipient
representative's identification number.
(C) A controlled substance recipient's date of birth.
(D) The national drug code number of a controlled substance
dispensed.
(E) The dates a controlled substance is dispensed.
(F) The quantities of a controlled substance dispensed.
(G) The number of days of supply dispensed.
(H) A dispenser's United States Drug Enforcement Agency
registration number.
(I) A prescriber's United States Drug Enforcement Agency
registration number.
(J) Whether a prescription was transmitted to the pharmacist
orally or in writing.
(2) Provide the advisory committee with continuing twenty-four
(24) hour a day online access to the data base.
(3) Secure the information collected and the data base
maintained against access by unauthorized persons.
(c) The advisory committee may execute a contract with a vendor
designated by the advisory committee to perform any function
associated with the administration of the INSPECT program.
(d) The INSPECT program may gather prescription data from the
Medicaid retrospective drug utilization review (DUR) program
established under IC 12-15-35.
(e) The advisory committee may accept and designate grants,
public and private financial assistance, and licensure fees to
provide funding for the INSPECT program.
As added by P.L.65-2006, SEC.11.
IC 35-48-7-11
Repealed
(Repealed by P.L.3-2008, SEC.269.)
IC 35-48-7-11.1
Confidentiality
Sec. 11.1. (a) This section applies after June 30, 2007.
(b) Information received by the INSPECT program under section
8.1 of this chapter is confidential.
(c) The advisory committee shall carry out a program to protect
the confidentiality of the information described in subsection
(b). The advisory committee may disclose the information to
another person only under subsection (d), (e), or (h).
(d) The advisory committee may disclose confidential information
described in subsection (b) to any person who is authorized to
engage in receiving, processing, or storing the information.
(e) Except as provided in subsections (f) and (g), the advisory
committee may release confidential information described in
subsection (b) to the following persons:
(1) A member of the board, the advisory committee, or another
governing body that licenses practitioners and is engaged in an
investigation, an adjudication, or a prosecution of a violation
under any state or federal law that involves a controlled
substance.
(2) An investigator for the consumer protection division of the
office of the attorney general, a prosecuting attorney, the
attorney general, a deputy attorney general, or an investigator
from the office of the attorney general, who is engaged in:
(A) an investigation;
(B) an adjudication; or
(C) a prosecution; of a violation under any state or federal law
that involves a controlled substance.
(3) A law enforcement officer who is an employee of:
(A) a local, state, or federal law enforcement agency; or
(B) an entity that regulates controlled substances or enforces
controlled substances rules or laws in another state; that is
certified to receive information from the INSPECT
program.
(4) A practitioner or practitioner's agent certified to receive
information from the INSPECT program.
(5) A controlled substance monitoring program in another state
with which Indiana has established an interoperability
agreement.
(f) Information provided to an individual under:
(1) subsection (e)(3) is limited to information:
(A) concerning an individual or proceeding involving the
unlawful diversion or misuse of a schedule II, III, IV, or V
controlled substance; and
(B) that will assist in an investigation or proceeding; and
(2) subsection (e)(4) may be released only for the purpose of:
(A) providing medical or pharmaceutical treatment; or
(B) evaluating the need for providing medical or pharmaceutical
treatment to a patient.
(g) Before the advisory committee releases confidential
information under subsection (e), the applicant must be approved
by the INSPECT program in a manner prescribed by the advisory
committee.
(h) The advisory committee may release to:
(1) a member of the board, the advisory committee, or another
governing body that licenses practitioners;
(2) an investigator for the consumer protection division of the
office of the attorney general, a prosecuting attorney, the
attorney general, a deputy attorney general, or an investigator
from the office of the attorney general; or
(3) a law enforcement officer who is:
(A) authorized by the state police department to receive the
type of information released; and
(B) approved by the advisory committee to receive the type of
information released;
confidential information generated from computer records that
identifies practitioners who are prescribing or dispensing large
quantities of a controlled substance.
(i) The information described in subsection (h) may not be
released until it has been reviewed by:
(1) a member of the advisory committee who is licensed in the
same profession as the prescribing or dispensing practitioner
identified by the data; or
(2) the advisory committee's designee; and until that member or
the designee has certified that further investigation is
warranted. However, failure to comply with this subsection does
not invalidate the use of any evidence that is otherwise
admissible in a proceeding described in subsection (j).
(j) An investigator or a law enforcement officer receiving
confidential information under subsection (d), (e), or (h) may
disclose the information to a law enforcement officer or an
attorney for the office of the attorney general for use as
evidence in the following:
(1) A proceeding under IC 16-42-20.
(2) A proceeding under any state or federal law that involves a
controlled substance.
(3) A criminal proceeding or a proceeding in juvenile court that
involves a controlled substance.
(k) The advisory committee may compile statistical reports from
the information described in subsection (b). The reports must
not include information that identifies any practitioner,
ultimate user, or other person administering a controlled
substance. Statistical reports compiled under this subsection
are public records.
(l) This section may not be construed to require a practitioner
to obtain information about a patient from the data base.
(m) A practitioner is immune from civil liability for an injury,
death, or loss to a person solely due to a practitioner seeking
or not seeking information from the INSPECT program. The civil
immunity described in this subsection does not extend to a
practitioner if the practitioner receives information directly
from the INSPECT program and then negligently misuses this
information. This subsection does not apply to an act or
omission that is a result of gross negligence or intentional
misconduct.
(n) The advisory committee may review the records of the INSPECT
program. If the advisory committee determines that a violation
of the law may have occurred, the advisory committee shall
notify the appropriate law enforcement agency or the relevant
government body responsible for the licensure, regulation, or
discipline of practitioners authorized by law to prescribe
controlled substances.
As added by P.L.65-2006, SEC.13.
IC 35-48-7-12
Repealed
(Repealed by P.L.3-2008, SEC.269.)
IC 35-48-7-12.1
Rules to implement chapter
Sec. 12.1. (a) This section applies after June 30, 2007.
(b) The advisory committee shall adopt rules under IC 4-22-2 to
implement this chapter, including the following:
(1) Information collection and retrieval procedures for the
INSPECT program, including the controlled substances to be
included in the program required under section 8.1 of this
chapter.
(2) Design for the creation of the data base required under
section 10.1 of this chapter.
(3) Requirements for the development and installation of online
electronic access by the advisory committee to information
collected by the INSPECT program.
(4) Identification of emergency situations or other
circumstances in which a practitioner may prescribe, dispense,
and administer a prescription drug specified in section 8.1 of
this chapter without a written prescription or on a form other
than a form specified in section 8.1(b)(4) of this chapter.
(c) The advisory committee may:
(1) Set standards for education courses for individuals
authorized to use the INSPECT program.
(2) Identify treatment programs for individuals addicted to
controlled substances monitored by the INSPECT program.
(3) Work with impaired practitioner associations to provide
intervention and treatment.
As added by P.L.65-2006, SEC.15.
IC 35-48-7-13
Repealed
(Repealed by P.L.3-2008, SEC.269.)
IC 35-48-7-13.1
Controlled substances data fund; establishment
Sec. 13.1. (a) This section applies after June 30, 2007.
(b) The controlled substances data fund is established to fund
the operation of the INSPECT program. The fund shall be
administered by the Indiana professional licensing agency.
(c) Expenses of administering the fund shall be paid from money
in the fund. The fund consists of grants, public and private
financial assistance, and sixteen percent (16%) of the
controlled substances registration fees imposed under rules
adopted under IC 35-48-3-1.
(d) The treasurer of state shall invest the money in the fund
not currently needed to meet the obligations of the fund in the
same manner as other public money may be invested.
(e) Money in the fund at the end of a state fiscal year does not
revert to the state general fund.
As added by P.L.65-2006, SEC.17.
IC 35-48-7-14
Violations of chapter; misdemeanor offense
Sec. 14. A person who knowingly or intentionally violates this
chapter commits a Class A misdemeanor.
As added by P.L.163-1994, SEC.5.
IC 35-48-7-15
Repealed
(Repealed by P.L.214-2001, SEC.1.) |
|
